Patrick Marcellin

Patrick Marcellin's AcademicInfluence.com Rankings

Patrick Marcellin

Philosophy

#3715

World Rank

#5951

Historical Rank

Logic

#1351

World Rank

#2081

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Patrick Marcellin's Degrees

PhD Biochemistry Université Paris Cité

Why Is Patrick Marcellin Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Patrick Marcellin's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. (2004) (2954)
Telaprevir for previously untreated chronic hepatitis C virus infection. (2011) (2539)
Randomised trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus (1998) (2325)
Boceprevir for previously treated chronic HCV genotype 1 infection. (2011) (1711)
Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. (2014) (1667)
Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C (2005) (1426)
Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study (2013) (1410)
Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. (2003) (1367)
Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. (2005) (1285)
Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. (2004) (1118)
Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. (2003) (1015)
Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT) (1998) (929)
Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. (2006) (879)
Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. (2004) (838)
Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. (2008) (677)
Controlled attenuation parameter (CAP): a novel VCTE™ guided ultrasonic attenuation measurement for the evaluation of hepatic steatosis: preliminary study and validation in a cohort of patients with chronic liver disease from various causes. (2010) (657)
Hepatitis C: the clinical spectrum of the disease. (1999) (624)
Long-Term Histologic Improvement and Loss of Detectable Intrahepatic HCV RNA in Patients with Chronic Hepatitis C and Sustained Response to Interferon- Therapy (1997) (614)
Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis. (2017) (603)
Treatment of chronic viral hepatitis. (1994) (572)
Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: a meta-analysis of individual patient data. (2006) (560)
Insulin resistance in chronic hepatitis C: association with genotypes 1 and 4, serum HCV RNA level, and liver fibrosis. (2008) (553)
Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon α‐2a (40 kd)/ribavirin therapy (2006) (543)
Accuracy of liver stiffness measurement for the diagnosis of cirrhosis in patients with chronic liver diseases (2006) (514)
Non‐invasive assessment of liver fibrosis by stiffness measurement in patients with chronic hepatitis B (2009) (505)
Pretreatment serum hepatitis C virus RNA levels and hepatitis C virus genotype are the main and independent prognostic factors of sustained response to interferon alfa therapy in chronic hepatitis C (1995) (501)
Early serum HBsAg drop: A strong predictor of sustained virological response to pegylated interferon alfa‐2a in HBeAg‐negative patients (2009) (483)
Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3. (2004) (471)
Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B. (2005) (462)
Influence of human immunodeficiency virus infection on chronic hepatitis B in homosexual men (1999) (455)
Assessment of biliary fibrosis by transient elastography in patients with PBC and PSC (2006) (455)
Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) - NCT01514890. (2013) (449)
Fibrosis and disease progression in hepatitis C (2002) (446)
Hepatitis B virus surface antigen levels: A guide to sustained response to peginterferon alfa‐2a in HBeAg‐negative chronic hepatitis B (2009) (430)
A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel (2011) (428)
Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial (2014) (408)
Eradication of Hepatitis C Virus Infection in Patients With Cirrhosis Reduces Risk of Liver and Non-Liver Complications. (2017) (403)
EASL International Consensus Conference on Hepatitis C (1999) (383)
STEATOSIS IN CHRONIC HEPATITIS C: WHY DOES IT REALLY MATTER? (2005) (379)
Diagnosis of Hepatic Fibrosis and Cirrhosis by Transient Elastography in HIV/Hepatitis C Virus-Coinfected Patients (2006) (364)
The influence of human immunodeficiency virus coinfection on chronic hepatitis C in injection drug users: A long‐term retrospective cohort study (2001) (355)
Effect of alcohol consumption on serum hepatitis C virus RNA and histological lesions in chronic hepatitis C (1998) (348)
Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study (2019) (343)
All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study (2014) (342)
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial. (2016) (341)
Recombinant human α‐interferon in patients with chronic non‐A, non‐B hepatitis: A multicenter randomized controlled trial from France (1991) (335)
Liver diseases: A major, neglected global public health problem requiring urgent actions and large‐scale screening (2018) (333)
Impact of peginterferon and ribavirin therapy on hepatocellular carcinoma: incidence and survival in hepatitis C patients with advanced fibrosis. (2010) (331)
Reverse transcriptase-PCR quantification of mRNA levels from cytochrome (CYP)1, CYP2 and CYP3 families in 22 different human tissues (2007) (328)
Eradication of hepatitis C virus in patients successfully treated for chronic hepatitis C. (2008) (324)
Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B. (2011) (323)
Sustained response of hepatitis B e antigen-negative patients 3 years after treatment with peginterferon alpha-2a. (2009) (317)
Hepatitis B surface antigen quantification: why and how to use it in 2011 - a core group report. (2011) (309)
Long‐term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigen–positive chronic hepatitis B (2008) (306)
Once‐daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment‐naïve genotype 1 hepatitis C: The randomized PILLAR study (2013) (295)
Global burden of disease (GBD) for hepatitis C (2004) (291)
Predicting response to peginterferon α-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B (2006) (280)
Peginterferon-2a and Ribavirin Combination Therapy in Chronic Hepatitis C (2004) (280)
Features associated with success rate and performance of FibroScan measurements for the diagnosis of cirrhosis in HCV patients: a prospective study of 935 patients. (2007) (279)
Combination of Tenofovir Disoproxil Fumarate and Peginterferon α-2a Increases Loss of Hepatitis B Surface Antigen in Patients With Chronic Hepatitis B. (2016) (279)
CMV drives clonal expansion of NKG2C+ NK cells expressing self‐specific KIRs in chronic hepatitis patients (2012) (276)
Report of an international workshop: Roadmap for management of patients receiving oral therapy for chronic hepatitis B. (2007) (276)
Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naive and treatment-experienced patients with genotype 4 chronic hepatitis C virus infection (PEARL-I): a randomised, open-label trial (2015) (273)
Effectiveness of telaprevir or boceprevir in treatment-experienced patients with HCV genotype 1 infection and cirrhosis. (2014) (272)
Ledipasvir and sofosbuvir in patients with genotype 1 hepatitis C virus infection and compensated cirrhosis: An integrated safety and efficacy analysis (2015) (256)
HBeAg and hepatitis B virus DNA as outcome predictors during therapy with peginterferon alfa‐2a for HBeAg‐positive chronic hepatitis B (2008) (247)
The state of hepatitis B and C in Europe: report from the hepatitis B and C summit conference * (2011) (245)
HCV direct‐acting antiviral agents: the best interferon‐free combinations (2014) (243)
Serum hepatitis B virus DNA levels and liver histology in inactive HBsAg carriers. (2002) (242)
Seven-Year Efficacy and Safety of Treatment with Tenofovir Disoproxil Fumarate for Chronic Hepatitis B Virus Infection (2014) (235)
Effect of peginterferon alfa‐2a on liver histology in chronic hepatitis C: A meta‐analysis of individual patient data (2004) (234)
96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection. (2018) (227)
Liver gene expression signature to predict response to pegylated interferon plus ribavirin combination therapy in patients with chronic hepatitis C (2007) (226)
Assessment of liver fibrosis using transient elastography in patients with alcoholic liver disease. (2008) (225)
Hepatitis B virus genotypes and virologic response in 694 patients in phase III studies of adefovir dipivoxil (2003) (224)
Efficacy of peginterferon alpha‐2b in chronic hepatitis delta: Relevance of quantitative RT‐PCR for follow‐up (2006) (218)
Influence of HIV infection on the response to interferon therapy and the long-term outcome of chronic hepatitis B. (2002) (218)
Pathogenesis, diagnosis and management of hepatitis C. (2000) (216)
Treatment of hepatitis C virus–related cirrhosis: A randomized, controlled trial of interferon alfa‐2b versus no treatment (1999) (214)
Treatment of hepatitis B e antigen positive chronic hepatitis with telbivudine or adefovir: a randomized trial. (2007) (213)
Evaluation of APRI and FIB-4 scoring systems for non-invasive assessment of hepatic fibrosis in chronic hepatitis B patients. (2016) (211)
No detectable resistance to tenofovir disoproxil fumarate after 6 years of therapy in patients with chronic hepatitis B (2014) (209)
Direct‐acting antivirals for the treatment of hepatitis C virus infection: optimizing current IFN‐free treatment and future perspectives (2016) (205)
The neglected hepatitis C virus genotypes 4, 5 and 6: an international consensus report (2010) (202)
Shorter durations and lower doses of peginterferon alfa‐2a are associated with inferior hepatitis B e antigen seroconversion rates in hepatitis B virus genotypes B or C (2011) (199)
Cost effectiveness of peginterferon α-2b plus ribavirin versus interferon α-2b plus ribavirin for initial treatment of chronic hepatitis C (2003) (197)
Efficacy of an interferon- and ribavirin-free regimen of daclatasvir, asunaprevir, and BMS-791325 in treatment-naive patients with HCV genotype 1 infection. (2014) (196)
Novel controlled attenuation parameter for noninvasive assessment of steatosis using Fibroscan®: validation in chronic hepatitis C (2012) (194)
IL28B polymorphism is associated with treatment response in patients with genotype 4 chronic hepatitis C. (2012) (192)
Hepatitis C: viral and host factors associated with non-response to pegylated interferon plus ribavirin (2010) (183)
High rates of HBsAg seroconversion in HBeAg-positive chronic hepatitis B patients responding to interferon: a long-term follow-up study. (2009) (183)
No resistance to tenofovir disoproxil fumarate detected after up to 144 weeks of therapy in patients monoinfected with chronic hepatitis B virus (2011) (179)
Twelve weeks posttreatment follow‐up is as relevant as 24 weeks to determine the sustained virologic response in patients with hepatitis C virus receiving pegylated interferon and ribavirin (2010) (179)
Re-treatment of Patients With Chronic Hepatitis C Who Do Not Respond to Peginterferon-2b (2009) (176)
Mortality related to chronic hepatitis B and chronic hepatitis C in France: evidence for the role of HIV coinfection and alcohol consumption. (2008) (175)
Therapy of hepatitis C: Patients with normal aminotransferase levels (1997) (173)
Prospective study on anti‐hepatitis C virus–positive patients with persistently normal serum alanine transaminase with or without detectable serum hepatitis C virus RNA (2001) (173)
The intraportal lymphoid nodule and its environment in chronic active hepatitis C: An immunohistochemical study (1993) (173)
Incidence of Hepatocellular Carcinoma After Direct Antiviral Therapy for HCV in Patients With Cirrhosis Included in Surveillance Programs. (2018) (170)
Liver gene expression signature of mild fibrosis in patients with chronic hepatitis C. (2005) (169)
Molecular profiling of early stage liver fibrosis in patients with chronic hepatitis C virus infection. (2005) (167)
Efficacy and safety of peginterferon alfa‐2a (40KD) plus ribavirin in hepatitis C patients with advanced fibrosis and cirrhosis (2010) (163)
New direct‐acting antivirals' combination for the treatment of chronic hepatitis C (2011) (161)
Changing of hepatitis C virus genotype patterns in France at the beginning of the third millenium: The GEMHEP GenoCII Study (2005) (159)
Impact of long‐term tenofovir disoproxil fumarate on incidence of hepatocellular carcinoma in patients with chronic hepatitis B (2015) (159)
Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS). (2015) (157)
Improvement of health-related quality of life and work productivity in chronic hepatitis C patients with early and advanced fibrosis treated with ledipasvir and sofosbuvir. (2015) (157)
Cryoglobulinemia with vasculitis associated with hepatitis C virus infection. (1993) (155)
Long-term outcome of hepatitis C infection after bone marrow transplantation. (2004) (154)
Telaprevir is effective given every 8 or 12 hours with ribavirin and peginterferon alfa-2a or -2b to patients with chronic hepatitis C. (2011) (154)
Peginterferon alfa-2A (40 KD) (PEGASYS) in combination with ribavirin (RBV): efficacy and safety results from a phase III, randomized, double-blind, multicentre study examining effect of duration of treatment and RBV dose (2002) (153)
Interferon alfa for chronic hepatitis B infection: Increased efficacy of prolonged treatment (1999) (153)
Hepatitis B and hepatitis C in 2009 (2009) (150)
A phase II dose‐escalating trial of clevudine in patients with chronic hepatitis B (2004) (148)
Tenofovir is effective alone or with emtricitabine in adefovir-treated patients with chronic-hepatitis B virus infection. (2010) (147)
Natural history of hepatitis B. (2005) (147)
Autoimmune chronic hepatitis exacerbated by alpha-interferon. (1992) (146)
Reversibility of thyroid dysfunction induced by recombinant alpha interferon in chronic hepatitis C (1993) (143)
Diabetes mellitus is an independent prognostic factor for major liver‐related outcomes in patients with cirrhosis and chronic hepatitis C (2014) (141)
Direct comparison of diagnostic performance of transient elastography in patients with chronic hepatitis B and chronic hepatitis C (2012) (141)
Randomized trial of daclatasvir and asunaprevir with or without PegIFN/RBV for hepatitis C virus genotype 1 null responders. (2014) (141)
Hepatitis C virus genotypes in France: relationship with epidemiology, pathogenicity and response to interferon therapy (1999) (140)
Treatment with ledipasvir and sofosbuvir improves patient‐reported outcomes: Results from the ION‐1, ‐2, and ‐3 clinical trials (2015) (135)
Hepatitis B surface antigen levels: association with 5-year response to peginterferon alfa-2a in hepatitis B e-antigen-negative patients (2012) (133)
Direct acting antivirals for the treatment of chronic hepatitis C: one pill a day for tomorrow (2012) (133)
Decrease in serum ALT and increase in serum HCV RNA during pregnancy in women with chronic hepatitis C. (2000) (132)
Liver fibrosis in chronic hepatitis C virus infection: differentiating minimal from intermediate fibrosis with perfusion CT. (2010) (130)
Evidence for a role of nonalcoholic steatohepatitis in hepatitis C: A prospective study (2007) (128)
Liver microRNA-21 is overexpressed in non-alcoholic steatohepatitis and contributes to the disease in experimental models by inhibiting PPARα expression (2015) (126)
Epidemiological characteristics and response to peginterferon plus ribavirin treatment of hepatitis C virus genotype 4 infection (2007) (126)
Liver fibrosis is not associated with steatosis but with necroinflammation in French patients with chronic hepatitis C (2003) (126)
Characteristics of patients with chronic hepatitis B in France: predominant frequency of HBe antigen negative cases. (2006) (125)
The protease inhibitor, GS‐9256, and non‐nucleoside polymerase inhibitor tegobuvir alone, with ribavirin, or pegylated interferon plus ribavirin in hepatitis C (2012) (125)
Predictive value of ALT levels for histologic findings in chronic hepatitis C: A European collaborative study (2002) (122)
Gene expression and hepatitis C virus infection (2008) (122)
Liver fibrosis in women with chronic hepatitis C: evidence for the negative role of the menopause and steatosis and the potential benefit of hormone replacement therapy (2006) (121)
1369 TELAPREVIR SUBSTANTIALLY IMPROVED SVR RATES ACROSS ALL IL28B GENOTYPES IN THE ADVANCE TRIAL (2011) (120)
Relapse of hepatitis C virus-associated mixed cryoglobulinemia vasculitis in patients with sustained viral response. (2008) (120)
1413 SIMEPREVIR (TMC435) WITH PEGINTERFERON/RIBAVIRIN FOR TREATMENT OF CHRONIC HCV GENOTYPE-1 INFECTION IN TREATMENT-NAÏVE PATIENTS: RESULTS FROM QUEST-2, A PHASE III TRIAL (2013) (119)
Predictors of sustained response to alpha interferon therapy in chronic hepatitis C. (1999) (119)
In vivo hepatic endoplasmic reticulum stress in patients with chronic hepatitis C (2010) (118)
Treatment of hepatitis C virus infection with direct‐acting antiviral agents: 100% cure? (2018) (118)
Predictors of sustained response to alpha interferon therapy in chronic hepatitis C. (1998) (113)
Hepatitis B surface antigen: association with sustained response to peginterferon alfa-2a in hepatitis B e antigen-positive patients (2013) (113)
A global view of hepatitis C: Physician knowledge, opinions, and perceived barriers to care (2013) (109)
Demonstration of hepatitis B virus DNA by polymerase chain reaction in the serum and the liver after spontaneous or therapeutically induced HBeAg to anti‐HBe or HBsAg to Anti‐HBs seroconversion in patients with chronic hepatitis B (1992) (109)
Predictive value of ALT levels for histologic findings in chronic hepatitis C: a European collaborative study. (2001) (109)
Hepatitis C virus infection, alpha interferon therapy and thyroid dysfunction. (1995) (106)
Efficacy of tenofovir disoproxil fumarate at 240 weeks in patients with chronic hepatitis B with high baseline viral load (2013) (106)
Persistence of hepatitis B virus DNA in serum and liver from patients with chronic hepatitis B after loss of HBsAg. (1997) (105)
HBsAg quantification: useful for monitoring natural history and treatment outcome (2014) (104)
High sustained virologic response rates in rapid virologic response patients in the large real‐world PROPHESYS cohort confirm results from randomized clinical trials (2012) (104)
Lack of benefit of escalating dosage of interferon alfa in patients with chronic hepatitis C. (1995) (103)
A phase I/II study of recombinant human interleukin-12 in patients with chronic hepatitis B. (2000) (102)
Genomics and HCV infection: progression of fibrosis and treatment response. (2012) (101)
Redevelopment of hepatitis B surface antigen after renal transplantation. (1991) (101)
Safety and efficacy of daclatasvir-sofosbuvir in HCV genotype 1-mono-infected patients. (2017) (100)
Hepatitis B surface antigen serum level is associated with fibrosis severity in treatment-naïve, e antigen-positive patients. (2013) (98)
Recombinant Interferon-α for Chronic Hepatitis C in Patients Positive for Antibody to Human Immunodeficiency Virus (1992) (97)
Lipoprotein lipase mediates hepatitis C virus (HCV) cell entry and inhibits HCV infection (2007) (95)
Complications and competing risks of death in compensated viral cirrhosis (ANRS CO12 CirVir prospective cohort) (2015) (95)
Kinetics of hepatitis B surface antigen loss in patients with HBeAg-positive chronic hepatitis B treated with tenofovir disoproxil fumarate. (2014) (94)
No detectable resistance to tenofovir disoproxil fumarate in HBeAg+ and HBeAg− patients with chronic hepatitis B after 8 years of treatment (2017) (92)
Efficacy and safety of simeprevir with PegIFN/ribavirin in naïve or experienced patients infected with chronic HCV genotype 4. (2015) (90)
Response to peginterferon alfa-2a (40KD) in HBeAg-negative CHB: on-treatment kinetics of HBsAg serum levels vary by HBV genotype. (2013) (89)
Pretransplantation interferon treatment and recurrence of hepatitis B virus infection after liver transplantation for hepatitis B–related end‐stage liver disease (1994) (88)
Treatment of hepatitis C. The 2002 French consensus (2003) (88)
Global Burden of Disease (GBD) for Hepatitis C The Global Burden of Hepatitis C Working Group (2004) (88)
Adherence to treatment and quality of life during hepatitis C therapy: a prospective, real‐life, observational study (2011) (88)
TWO YEAR TENOFOVIR DISOPROXIL FUMARATE (TDF) TREATMENT AND ADEFOVIR DIPIVOXIL (ADV) SWITCH DATA IN HBEAG-NEGATIVE PATIENTS WITH CHRONIC HEPATITIS B (STUDY 102), PRELIMINARY ANALYSIS (2008) (88)
Validation of Baveno VI Criteria for Screening and Surveillance of Esophageal Varices in Patients With Compensated Cirrhosis and a Sustained Response to Antiviral Therapy. (2019) (87)
Cryoglobulinemia is associated with steatosis and fibrosis in chronic hepatitis C (2006) (86)
Hepatitis after intravenous buprenorphine misuse in heroin addicts. (2001) (86)
Insulin resistance and response to telaprevir plus peginterferon α and ribavirin in treatment-naïve patients infected with HCV genotype 1 (2012) (86)
Changes in liver fibrosis at the end of alpha interferon therapy and 6 to 18 months later in patients with chronic hepatitis C: quantitative assessment by a morphometric method. (1998) (84)
Safety and tolerability of ledipasvir/sofosbuvir with and without ribavirin in patients with chronic hepatitis C virus genotype 1 infection: Analysis of phase III ION trials (2015) (82)
Virological response at 4 weeks to predict outcome of hepatitis C treatment with pegylated interferon and ribavirin (2008) (81)
Peginterferon lambda for the treatment of HBeAg-positive chronic hepatitis B: A randomized phase 2b study (LIRA-B). (2016) (80)
Protease and polymerase inhibitors for the treatment of hepatitis C (2009) (79)
Effect on HBs antigen clearance of addition of pegylated interferon alfa-2a to nucleos(t)ide analogue therapy versus nucleos(t)ide analogue therapy alone in patients with HBe antigen-negative chronic hepatitis B and sustained undetectable plasma hepatitis B virus DNA: a randomised, controlled, open- (2017) (79)
Insulin resistance and geographical origin: major predictors of liver fibrosis and response to peginterferon and ribavirin in HCV-4 (2009) (78)
Long-term efficacy and safety of emtricitabine plus tenofovir DF vs. tenofovir DF monotherapy in adefovir-experienced chronic hepatitis B patients. (2014) (78)
Long‐term clearance of hepatitis C virus following interferon α‐2b or peginterferon α‐2b, alone or in combination with ribavirin (2013) (77)
Hepatitis B virus genotypes and virologic response in 694 patients in phase III studies of adefovir dipivoxil1. (2003) (77)
Interferon free therapy with direct acting antivirals for HCV (2013) (76)
Prediction of disease reactivation in asymptomatic hepatitis B e antigen-negative chronic hepatitis B patients using baseline serum measurements of HBsAg and HBV-DNA. (2013) (76)
Nomogram for individualized prediction of hepatocellular carcinoma occurrence in hepatitis C virus cirrhosis (ANRS CO12 CirVir) (2016) (76)
A randomized, placebo‐controlled study to evaluate the efficacy of 12‐month famciclovir treatment in patients with chronic hepatitis B e antigen–positive hepatitis B (2000) (76)
Efficacy and Safety of Two-Dose Regimens of Peginterferon Alpha-2a Compared with Interferon Alpha-2a in Chronic Hepatitis C: A Multicenter, Randomized Controlled Trial (2004) (76)
Cytokine--chemokine and apoptotic signatures in patients with hepatitis C. (2007) (75)
Influence of genotype on hepatitis B surface antigen kinetics in hepatitis B e antigen-negative patients treated with pegylated interferon-α2a (2009) (73)
Cytokines as predictors for sustained response and as markers for immunomodulation in patients with chronic hepatitis C. (2001) (72)
Danoprevir, an HCV NS3/4A protease inhibitor, improves insulin sensitivity in patients with genotype 1 chronic hepatitis C (2010) (72)
Kinetics of serum cytokines reflect changes in the severity of chronic hepatitis C presenting minimal fibrosis (2002) (72)
Genetics, genomics, and proteomics: implications for the diagnosis and the treatment of chronic hepatitis C. (2007) (71)
Shaving as potential source of hepatitis C virus infection (1995) (70)
Ten‐year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B virus infection (2019) (69)
Rapid Viral Response of Once-Daily Tmc435 plus Pegylated Interferon/Ribavirin in Hepatitis C Genotype-1 Patients: A Randomized Trial (2011) (69)
Compliance With Hepatocellular Carcinoma Surveillance Guidelines Associated With Increased Lead-Time Adjusted Survival of Patients With Compensated Viral Cirrhosis: A Multi-Center Cohort Study. (2018) (69)
Persistence of hepatitis B virus DNA demonstrated by polymerase chain reaction in serum and liver after loss of HBsAg induced by antiviral therapy. (1990) (68)
Clinical course of spontaneous reactivation of hepatitis B virus infection in patients with chronic hepatitis B (1990) (68)
P.102 Long-term adefovir dipivoxil treatment induces regression of liver fibrosis in patients with HBeAg-negative chronic hepatitis B: results after 5 years of therapy (2006) (68)
Comparing the safety, tolerability and quality of life in patients with chronic hepatitis B vs chronic hepatitis C treated with peginterferon alpha‐2a (2008) (67)
Treatment of chronic hepatitis C patients with the NS3/4A protease inhibitor danoprevir (ITMN-191/RG7227) leads to robust reductions in viral RNA: a phase 1b multiple ascending dose study. (2011) (67)
Hepatitis C virus (HCV) viremia in human immunodeficiency virus-seronegative and -seropositive patients with indeterminate HCV recombinant immunoblot assay. (1994) (66)
Influence of Hepatitis G Virus Infection on the Severity of Liver Disease and Response to Interferon- in Patients with Chronic Hepatitis C (1997) (66)
Comparison of anti-HBe-positive and HBe-antigen-positive chronic hepatitis B in France. French Multicentre Group. (1994) (66)
The role of HBsAg quantification for monitoring natural history and treatment outcome (2013) (64)
Second‐wave IFN‐based triple therapy for HCV genotype 1 infection: simeprevir, faldaprevir and sofosbuvir (2014) (64)
Expression of cytokine-dependent immune adhesion molecules by hepatocytes and bile duct cells in chronic hepatitis C. (1994) (62)
Retreatment of chronic hepatitis B e antigen–positive patients with recombinant interferon alfa‐2a (1999) (62)
Effectiveness and Safety of Tenofovir Disoproxil Fumarate in Chronic Hepatitis B: A 3-Year, Prospective, Real-World Study in France (2016) (62)
Changes in autophagic response in patients with chronic hepatitis C virus infection. (2011) (62)
Sustained hypothyroidism induced by recombinant alpha interferon in patients with chronic hepatitis C. (1992) (60)
HBsAg quantification to optimize treatment monitoring in chronic hepatitis B patients (2015) (59)
The negative impact of HBV/HCV coinfection on cirrhosis and its consequences (2017) (59)
A new step toward standardization of serum hepatitis C Virus–RNA quantification in patients with chronic hepatitis C (2000) (58)
Second generation (RIBA) test in diagnosis of chronic hepatitis C (1991) (57)
Long-term clinical outcomes in cirrhotic chronic hepatitis B patients treated with tenofovir disoproxil fumarate for up to 5 years (2015) (57)
Vaniprevir with pegylated interferon alpha‐2a and ribavirin in treatment‐naïve patients with chronic hepatitis C: A randomized phase II study (2012) (57)
High predictive value of early viral kinetics in retreatment with peginterferon and ribavirin of chronic hepatitis C patients non-responders to standard combination therapy. (2007) (57)
1412 INTERFERON-FREE TREATMENT WITH A COMBINATION OF MERICITABINE AND DANOPREVIR/R WITH OR WITHOUT RIBAVIRIN IN TREATMENT-NAIVE HCV GENOTYPE 1-INFECTED PATIENTS (2012) (56)
Fibrosis and disease progression in hepatitis C (2002) (55)
Recombinant alpha interferon for chronic hepatitis B in anti-HIV positive patients receiving zidovudine. (1993) (55)
Review article: management of patients with chronic hepatitis C virus infection and ‘normal’ alanine aminotransferase activity (2006) (54)
Refinement of stopping rules during treatment of hepatitis C genotype 1 infection with boceprevir and peginterferon/ribavirin (2012) (54)
104 BOCEPREVIR (B) COMBINATION THERAPY IN NULL RESPONDERS (NR): RESPONSE DEPENDENT ON INTERFERON RESPONSIVENESS (2008) (53)
Bacterial infection in compensated viral cirrhosis impairs 5-year survival (ANRS CO12 CirVir prospective cohort) (2015) (53)
Telbivudine plus pegylated interferon alfa-2a in a randomized study in chronic hepatitis B is associated with an unexpected high rate of peripheral neuropathy. (2015) (53)
Mesalazine (5-aminosalicylic acid) induced chronic hepatitis (1999) (52)
Steatosis is an independent predictor of relapse following rapid virologic response in patients with HCV genotype 3. (2011) (51)
Association of baseline vitamin D levels with clinical parameters and treatment outcomes in chronic hepatitis B. (2015) (51)
Ectopic hepatocellular carcinoma arising in the left chest wall: a long-term follow-up. (2001) (51)
Impact of adefovir dipivoxil on liver fibrosis and activity assessed with biochemical markers (FibroTest–ActiTest) in patients infected by hepatitis B virus (2009) (50)
Deep sequencing shows that HBV basal core promoter and precore variants reduce the likelihood of HBsAg loss following tenofovir disoproxil fumarate therapy in HBeAg-positive chronic hepatitis B (2016) (50)
Occult infection of peripheral B cells by hepatitis C variants which have low translational efficiency in cultured hepatocytes (2010) (50)
Hepatic steatosis in chronic hepatitis C: baseline host and viral characteristics and influence on response to therapy with peginterferon α‐2a plus ribavirin (2007) (49)
Repeated Measurements of Hepatitis B Surface Antigen Identify Carriers of Inactive HBV During Long-term Follow-up. (2016) (49)
Treatment of chronic hepatitis B (2005) (48)
Which patients with genotype 1 chronic hepatitis C can benefit from prolonged treatment with the 'accordion' regimen? (2007) (48)
Markers of Inflammation and Fibrosis in Alcoholic Hepatitis and Viral Hepatitis C (2011) (48)
Baseline HBsAg and HBcrAg titres allow peginterferon‐based ‘precision medicine’ in HBeAg‐negative chronic hepatitis B patients (2016) (48)
SERUM TUMOUR NECROSIS FACTOR-α AND TRANSFORMING GROWTH FACTOR-β LEVELS IN CHRONIC HEPATITIS C PATIENTS ARE IMMUNOMODULATED BY THERAPY (2002) (47)
Prognostic value of viral eradication for major adverse cardiovascular events in hepatitis C cirrhotic patients (2018) (47)
Treatment of Hepatitis C Virus Genotype 4–Related Cirrhosis: Ribavirin and Interferon Combination Compared With Interferon Alone (2002) (47)
Sustained virological response is associated with clearance of hepatitis C virus RNA and a decrease in hepatitis C virus antibody (2009) (47)
Clinical relevance of total HCV Core antigen testing for hepatitis C monitoring and for predicting patients’ response to therapy (2003) (47)
Sarcoidosis during combined interferon alfa and ribavirin therapy in 2 patients with chronic hepatitis C. (2002) (46)
New and emerging treatment of chronic hepatitis B. (2007) (46)
Prednisolone withdrawal therapy enhances the effect of human lymphoblastoid interferon in chronic hepatitis B. INTERPRED Trial Group. (1996) (46)
Influence of cirrhosis on lamotrigine pharmacokinetics. (2001) (45)
Improved response to ribavirin interferon combination compared with interferon alone in patients with type 4 chronic hepatitis C without cirrhosis. (2000) (45)
Treatment of chronic hepatitis C virus in allogeneic bone marrow transplant recipients (2005) (45)
[8] SHOULD TREATMENT WITH PEGINTERFERON PLUS RIBAVIRIN BE INTENSIFIED IN PATIENTS WITH HCV GENOTYPE 2/3 WITHOUT A RAPID VIROLOGICAL RESPONSE? (2007) (45)
Boceprevir for chronic HCV genotype 1 infection in patients with prior treatment failure to peginterferon/ribavirin, including prior null response. (2014) (45)
Evolution of hepatitis B viral load and viral genome sequence during adefovir dipivoxil therapy (2004) (44)
Failure of acyclovir to enhance the antiviral effect of alpha lymphoblastoid interferon on HBe-seroconversion in chronic hepatitis B. A multi-centre randomized controlled trial. (1992) (44)
Sequential therapy with adefovir dipivoxil and pegylated Interferon Alfa‐2a for HBeAg‐negative patients (2011) (44)
1094 100% SVR IN IL28B CC PATIENTS TREATED WITH 12 WEEKS OF TELAPREVIR, PEGINTERFERON AND RIBAVIRIN IN THE PROVE2 TRIAL (2012) (44)
Patient education improves adherence to peg-interferon and ribavirin in chronic genotype 2 or 3 hepatitis C virus infection: a prospective, real-life, observational study. (2008) (44)
Safety and efficacy of viramidine versus ribavirin in ViSER2: randomized, double-blind study in therapy-naive hepatitis C patients. (2010) (43)
Impact of controlled attenuation parameter on detecting fibrosis using liver stiffness measurement (2018) (43)
Long‐term therapy for chronic hepatitis B: Hepatitis B virus DNA suppression leading to cirrhosis reversal (2013) (43)
11 SUSTAINED VIROLOGIC RESPONSE (SVR) IN PRIOR PEGINTERFERON/RIBAVIRIN (PR) TREATMENT FAILURES AFTER RETREATMENT WITH BOCEPREVIR (BOC)-+-PR: THE PROVIDE STUDY INTERIM RESULTS (2012) (41)
The combination of MK-5172, peginterferon, and ribavirin is effective in treatment-naive patients with hepatitis C virus genotype 1 infection without cirrhosis. (2014) (41)
Effectiveness of interferon plus ribavirin combination in the treatment of naive patients with hepatitis C virus type 5. A French multicentre retrospective study (2006) (41)
Effectiveness of chronic hepatitis C treatment in drug users in routine clinical practice: results of a prospective cohort study (2010) (41)
Balapiravir plus peginterferon alfa-2a (40KD)/ribavirin in a randomized trial of hepatitis C genotype 1 patients. (2012) (41)
69 NEPTUNE STUDY: ON-TREATMENT HBSAG LEVEL ANALYSIS CONFIRMS PREDICTION OF RESPONSE OBSERVED IN PHASE 3 STUDY OF PEGINTERFERON ALFA-2A IN HBEAG-POSITIVE PATIENTS (2011) (40)
103 VIROLOGICAL AND BIOCHEMICAL RESPONSE IN PATIENTS WITH HBEAG-NEGATIVE CHRONIC HEPATITIS B TREATED WITH PEGINTERFERON ALFA-2A (40KD) WITH OR WITHOUT LAMIVUDINE: RESULTS OF 4-YEAR FOLLOW-UP (2008) (40)
Second infection with a different hepatitis C virus genotype in a intravenous drug user during interferon therapy (2003) (40)
46 Three year study of adefovir dipivoxil (ADV) demonstrates sustained efficacy in presumed precore mutant chronic hepatitis B (CHB) patients in a long term safety and efficacy study (LTSES) (2004) (39)
Integrin up‐regulation in chronic liver disease: relationship with inflammation and fibrosis in chronic hepatitis C (2001) (39)
Quantification of hepatitis B surface antigen: a new concept for the management of chronic hepatitis B (2011) (39)
43 LONG TERM TENOFOVIR DISOPROXIL FUMARATE (TDF) THERAPY AND THE RISK OF HEPATOCELLULAR CARCINOMA (2013) (38)
Response to antiviral treatment in patients infected with hepatitis B virus genotypes E–H (2009) (38)
Low frequency of precore hepatitis B virus mutants in anti‐hepatitis B e—positive reactivation after loss of hepatitis B e antigen in patients with chronic hepatitis B (1995) (38)
MicroRNA-based diagnostic tools for advanced fibrosis and cirrhosis in patients with chronic hepatitis B and C (2016) (38)
Impact of TT virus infection in acute and chronic, viral- and non viral-related liver diseases. (2000) (38)
LO3 : Safety and efficacy of the combination daclatasvir-sofosbuvir in HCV genotype 1-mono-infected patients from the french observational cohort ANRS CO22 hepather* (2015) (38)
Pegylated interferon alfa-2B (PEG-intron) mono-therapy is superior to interferon alfa-2B (intron A) for the treatment of chronic hepatitis C (2000) (38)
Resistance to adefovir: a new challenge in the treatment of chronic hepatitis B. (2005) (37)
Recombinant human γ‐interferon in patients with chronic active hepatitis B: Pharmacokinetics, tolerance and biological effects (1990) (37)
Reactivity to c33c antigen as a marker of hepatitis C virus multiplication. (1992) (36)
No Resistance to Tenofovir Alafenamide Detected through 96 Weeks of Treatment in Patients with Chronic Hepatitis B Infection (2018) (36)
Safety and efficacy of peginterferon plus ribavirin in patients with chronic hepatitis C and bridging fibrosis or cirrhosis (2005) (35)
Hepatitis B Surface Antigen Loss with Tenofovir Disoproxil Fumarate Plus Peginterferon Alfa-2a: Week 120 Analysis (2018) (35)
Antiviral Activity of ANA773, an Oral Inducer of Endogenous Interferons that Acts Via TLR7, in Chronic Hepatitis C Patients (2011) (35)
Chronic hepatitis C: Interferon retreatment of relapsers. A meta‐analysis of individual patient data (1999) (34)
Durability of Hepatitis B Surface Antigen Loss With Nucleotide Analogue and Peginterferon Therapy in Patients With Chronic Hepatitis B (2019) (34)
Improving performance of liver biopsy in fibrosis assessment. (2014) (34)
Predictors of response to tenofovir disoproxil fumarate plus peginterferon alfa‐2a combination therapy for chronic hepatitis B (2016) (34)
Further analysis is required to identify an early stopping rule for peginterferon therapy that is valid for all hepatitis B e antigen–positive patients (2011) (34)
Randomized controlled trial of adenine arabinoside 5′‐monophosphate in chronic active hepatitis B: Comparison of the efficacy in heterosexual and homosexual patients (1989) (34)
917 ON-TREATMENT MONITORING OF HBsAg LEVELS TO PREDICT RESPONSE TO PEGINTERFERON ALFA-2A IN PATIENTS WITH HBeAg-POSITIVE CHRONIC HEPATITIS B (2009) (33)
57 TENOFOVIR DISOPROXIL FUMARATE (TDF) FOR THE TREATMENT OF HBEAG-NEGATIVE CHRONIC HEPATITIS B: WEEK 72 TDF DATA AND WEEK 24 ADEFOVIR DIPIVOXIL SWITCH DATA (STUDY 102) (2008) (33)
Allogeneic hematopoietic cell transplant in HCV-infected patients. (2008) (33)
1423 INTERIM ANALYSIS OF AN INTERFERON (IFN)- AND RIBAVIRIN (RBV)-FREE REGIMEN OF DACLATASVIR (DCV), ASUNAPREVIR (ASV), AND BMS-791325 IN TREATMENT-NAIVE, HEPATITIS C VIRUS GENOTYPE 1-INFECTED PATIENTS (2013) (32)
Simeprevir (TMC435) with Peginterferon/Ribavirin for treatment of chronic HCV genotype 1 infection in treatment-naïve european patients in the quest-1 and quest-2 phase III trials (2014) (32)
Serum proteome to predict virologic response in patients with hepatitis C treated by pegylated interferon plus ribavirin. (2006) (32)
924 INCREASING RATES OF HBsAg CLEARANCE AND SEROCONVERSION IN PATIENTS WITH HBeAg-NEGATIVE DISEASE TREATED WITH PEGINTERFERON ALFA-2A ± LAMIVUDINE: RESULTS OF 5-YEAR POST-TREATMENT FOLLOW UP (2009) (32)
725 QUANTITATIVE HBSAG: A NEW SPECIFIC MARKER FOR THE DIAGNOSIS OF HBSAG INACTIVE CARRIAGE (2010) (32)
Quantitation of hepatic hepatitis C virus RNA in patients with chronic hepatitis C. Relationship with severity of disease, viral genotype and response to treatment. (2001) (32)
Re‐treatment with interferon alfa of patients with chronic hepatitis C (1998) (32)
P1319 ONCE-DAILY SIMEPREVIR (TMC435) WITH PEGINTERFERON/RIBAVIRIN IN TREATMENT-NAIVE OR TREATMENT-EXPERIENCED CHRONIC HCV GENOTYPE 4-INFECTED PATIENTS: FINAL RESULTS OF A PHASE III TRIAL (2014) (32)
Detection and quantitation of serum HCV-RNA by branched DNA amplification in anti-HCV positive blood donors. (1994) (32)
Tenofovir disoproxil fumarate (TDF) for the treatment of HBeAg-negative chronic Hepatitis B: Week 72 TDF data and week 24 Adefovir dipivoxil switch data (Study 102) (2008) (31)
Quantification of hepatitis C virus RNA in serum by branched DNA-based signal amplification assays. (1999) (31)
Hepatitis C virus genotypes in France: relationship with epidemiology, pathogenicity and response to interferon therapy. The GEMHEP. (1999) (31)
O58 RESULTS FROM THE PHASE 2 PEARL-I STUDY: INTERFERON-FREE REGIMENS OF ABT-450/R + ABT-267 WITH OR WITHOUT RIBAVIRIN IN PATIENTS WITH HCV GENOTYPE 4 INFECTION (2014) (31)
Auxiliary liver transplantation for fulminant hepatitis B: Results from a series of six patients with special emphasis on regeneration and recurrence of hepatitis B (2002) (31)
13 TELBIVUDINE (LDT) PLUS PEG-INTERFERON (PEGIFN) IN HBEAG-POSITIVE CHRONIC HEPATITIS B – VERY POTENT ANTIVIRAL EFFICACY BUT RISK OF PERIPHERAL NEUROPATHY (PN) (2010) (30)
LP28 : Efficacy of the oral sofosbuvir-based combinations in HCV genotype 4-mono-infected patients from the french observational cohort anrs CO22 hepather (2015) (30)
Pharmacokinetic/Pharmacodynamic and Time-to-Event Models of Ribavirin-Induced Anaemia in Chronic Hepatitis C (2005) (30)
Chronic non-B, non-C hepatitis among blood donors assessed with HCV third generation tests and polymerase chain reaction. (1993) (30)
Extrahepatic cancers are the leading cause of death in patients achieving hepatitis B virus control or hepatitis C virus eradication (2018) (30)
Future treatments for hepatitis delta virus infection (2020) (30)
Hypervariable region 1 quasispecies in hepatitis C virus genotypes 1b and 3 infected patients with normal and abnormal alanine aminotransferase levels (2002) (29)
Transient elastography in chronic viral hepatitis: a critical appraisal (2011) (29)
50 Durability of response and occurrence of late response to peginterferon alpha-2a (40KD) [PEGASYS] one year post-treatment in patients with HBeAg-positive chronic hepatitis B (2006) (29)
Reduction of MicroRNA 122 Expression in IFNL3 CT/TT Carriers and during Progression of Fibrosis in Patients with Chronic Hepatitis C (2014) (29)
Pegylated Interferon-α2A plus Ribavirin for Chronic Hepatitis C in a Real-Life Setting: The Hepatys French Cohort (2003–2007) (2012) (29)
Advances in therapy for chronic hepatitis B. (2002) (29)
Optimal IFN‐free therapy in treatment‐naïve patients with HCV genotype 1 infection (2015) (29)
Incidence of dysthyroidism during interferon therapy in chronic hepatitis C. (1997) (29)
Rationale and design of the REPEAT study: a phase III, randomized, clinical trial of peginterferon alfa-2a (40 kDa) plus ribavirin in non-responders to peginterferon alfa-2b (12 kDa) plus ribavirin (2005) (29)
Long-term histologic and viral changes in patients with chronic hepatitis C who responded to alpha interferon. (2008) (28)
HIV coinfection does not compromise liver histological response to interferon therapy in patients with chronic hepatitis C (2002) (28)
Hepatitis C virus infection in anti-HIV positive and negative French homosexual men with chronic hepatitis: comparison of second- and third-generation anti-HCV testing. (2008) (27)
Serum tumour necrosis factor-alpha and transforming growth factor-beta levels in chronic hepatitis C patients are immunomodulated by therapy. (2002) (27)
Clinical trial: effects of adefovir dipivoxil therapy in Asian and Caucasian patients with chronic hepatitis B (2007) (27)
Mericitabine and ritonavir‐boosted danoprevir with or without ribavirin in treatment‐naive HCV genotype 1 patients: INFORM‐SVR study (2015) (27)
alpha-Interferon-induced rejection of a hepatitis C virus-infected liver allograft tolerated with a low dosage immunosuppressive regimen. (1995) (27)
Randomized controlled trial of danoprevir plus peginterferon alfa-2a and ribavirin in treatment-naïve patients with hepatitis C virus genotype 1 infection. (2013) (27)
Viral Suppression and Cirrhosis Regression with Tenofovir Disoproxil Fumarate in Asians with Chronic Hepatitis B (2014) (27)
Serum alanine transaminase level is a good predictor of response to interferon alfa therapy for chronic hepatitis B in human immunodeficiency virus-infected patients. (2000) (27)
Retreatment with recombinant interferon-alpha in patients with chronic hepatitis C. (1993) (27)
IFNL3 (IL28B) polymorphism does not predict long‐term response to interferon therapy in HBeAg‐positive chronic hepatitis B patients (2014) (26)
Fatal cardiomyopathy associated with pegylated interferon/ribavirin in a patient with chronic hepatitis C. (2006) (26)
Tolerability of Treatments for Viral Hepatitis (2001) (26)
Virological analysis of patients receiving Telaprevir administered Q8H or Q12H with Peginterferon-Alfa-2A or -Alfa-2B and Ribavirin in treatment-naive patients with Genotype I hepatitis C: study C208 (2009) (26)
76 TENOFOVIR DISOPROXIL FUMARATE (TDF) VERSUS EMTRICITABINE PLUS TDF FOR TREATMENT OF CHRONIC HEPATITIS B (CHB) IN SUBJECTS WITH PERSISTENT VIRAL REPLICATION RECEIVING ADEFOVIR DIPIVOXIL (ADV) (2008) (26)
ALT flares during nucleotide analogue therapy are associated with HBsAg loss in genotype A HBeAg‐positive chronic hepatitis B (2018) (26)
Phase 2 study of the combination of merimepodib with peginterferon-alpha2b, and ribavirin in nonresponders to previous therapy for chronic hepatitis C. (2007) (26)
740 HBSAG KINETICS IN PATIENTS WITH CHRONIC HEPATITIS B (CHB) TREATED WITH TENOFOVIR DISOPROXIL FUMARATE (TDF) FOR UP TO 4 YEARS (2011) (25)
Hepatitis C virus genotypes in French blood donors (1995) (25)
Safety and efficacy of stopping tenofovir disoproxil fumarate in patients with chronic hepatitis B following at least 8 years of therapy: a prespecified follow-up analysis of two randomised trials. (2019) (25)
Evidence of Hepatitis C Virus Viremia without Detectable Antibody to Hepatitis C Virus in a Blood Donor (2000) (25)
Chronic hepatitis B: a global health problem requiring coherent worldwide treatment strategies (2007) (25)
Prolonged interferon‐alpha therapy of hepatitis B virus‐related decompensated cirrhosis (1997) (24)
Clinical performances of two real-time PCR assays and bDNA/TMA to early monitor treatment outcome in patients with chronic hepatitis C. (2009) (24)
An update in the management of chronic hepatitis B. (2013) (24)
The current status of antiviral therapy of chronic hepatitis B. (2005) (24)
Recombinant interferon-alpha for chronic hepatitis C in patients positive for antibody to human immunodeficiency virus. Comité des Anti-Viraux. (1992) (24)
Clinical trial: a phase II, randomized study evaluating the safety, pharmacokinetics and anti‐viral activity of clevudine for 12 weeks in patients with chronic hepatitis B (2008) (24)
Interferon therapy for chronic hepatitis B. (2007) (24)
Subfulminant syncytial giant cell hepatitis: recurrence after liver transplantation treated with ribavirin. (1997) (23)
Efficacy and safety of lactosaminated human serum albumin-adenine arabinoside monophosphate in chronic hepatitis B patients non-responders to interferon therapy: a randomised clinical trial. (2001) (23)
THREE YEARS OF TENOFOVIR DISOPROXIL (TDF) TREATMENT IN HBEAG-POSITIVE PATIENTS (HBEAG plus ) WITH CHRONIC HEPATITIS B (STUDY 103), PRELIMINARY ANALYSIS (2009) (23)
Persistent delta antigenaemia in chronic delta hepatitis and its relation with human immunodeficiency virus infection (1992) (23)
Anti—pre‐S responses and viral clearance in chronic hepatitis B virus infection (1992) (23)
Significant gene expression differences in histologically “Normal” liver biopsies: Implications for control tissue (2008) (23)
[10] THE SAFETY AND EFFICACY OF TARIBAVIRIN PLUS PEGYLATED INTERFERON ALFA-2a VERSUS RIBAVIRIN PLUS PEGYLATED INTERFERON ALFA-2a IN THERAPY-NAIVE PATIENTS INFECTED WITH HCV: PHASE 3 RESULTS (2007) (23)
ROLE OF REPLICATIVE SENESCENCE IN THE PROGRESSION OF FIBROSIS IN HEPATITIS C VIRUS (HCV) RECURRENCE AFTER LIVER TRANSPLANTATION (2004) (23)
[53] VIROLOGICAL AND BIOCHEMICAL RESPONSE IN PATIENTS WITH HBeAg-NEGATIVE CHB TREATED WITH PEGINTERFERON a-2a (40 kD) ± LAMIVUDINE: 3-YEAR FOLLOW-UP RESULTS (2007) (23)
A phase 2 study of filibuvir in combination with pegylated IFN alfa and ribavirin for chronic HCV. (2014) (22)
424 Durability of HBEAG seroconversion after adefovir dipivoxil treatment for chronic hepatitis B (CHB) (2004) (22)
Chronic hepatitis B: back to the future with HBsAg (2009) (22)
GEMHEP multicenter quality control study of PCR detection of GB virus C/hepatitis G virus RNA in serum (1997) (22)
Metabolic disorders associated with chronic hepatitis C: impact of genotype and ethnicity (2010) (22)
Refined prediction of week 12 response and SVR based on week 4 response in HCV genotype 1 patients treated with peginterferon alfa-2a (40KD) and ribavirin. (2012) (22)
Treatment of hepatitis C patients with normal aminotransferases levels. (1999) (21)
Infection by hepatitis C virus through contaminated intravenous immune globulin: results of a prospective national inquiry in France (1996) (21)
Antiviral activity of danoprevir (ITMN-191/RG7227) in combination with pegylated interferon α-2a and ribavirin in patients with hepatitis C. (2011) (21)
Precore/Core promoter variants to predict significant fibrosis in both HBeAg positive and negative chronic hepatitis B (2015) (21)
Retreatment with interferon-α of chronic hepatitis C virus infection (1994) (21)
85 ANTIVIRAL ACTIVITY AND SAFETY OF ITMN-191 IN COMBINATION WITH PEGINTERFERON ALFA-2A AND RIBAVIRIN IN PATIENTS WITH CHRONIC HEPATITIS C VIRUS (HCV) (2009) (21)
O166 ALL-ORAL DUAL THERAPY WITH DACLATASVIR AND ASUNAPREVIR IN PATIENTS WITH HCV GENOTYPE 1B INFECTION: PHASE 3 STUDY RESULTS (2014) (21)
Early virological response in six patients with hepatitis D virus infection and compensated cirrhosis treated with Bulevirtide in real‐life (2021) (21)
1180 A CHROMOSOME 19 SNP (RS12979860) PREDICTS OUTCOME (EVR/SVR) IN HCV PATIENTS TREATED WITH INTERFERON, INDEPENDENT OF PEGYLATION OR RIBAVIRIN (2010) (20)
Hepatitis B e Antigen Status and Hepatitis B DNA Levels in Women of Childbearing Age with Chronic Hepatitis B Infection Screening for Clinical Trials (2015) (20)
A Randomized Trial of Telbivudine (LdT) vs Adefovir for HBeAg-positive Chronic Hepatitis B: Final Week 52 results (2006) (20)
Serum Levels of Hepatitis B Surface Antigen Predict Severity of Fibrosis in Patients With E Antigen-Positive Chronic Hepatitis B. (2015) (20)
Long-term efficacy and safety of adefovir dipivoxil for the treatment of HBeAg-positive chronic hepatitis B (CHB) patients (2006) (20)
Diagnostic performance of controlled attenuation parameter for predicting steatosis grade in chronic hepatitis B. (2015) (20)
Reinforced interferon alpha‐2b and ribavirin is more effective than standard combination therapy in the retreatment of chronic hepatitis C previously nonresponsive to interferon: a randomized trial (2003) (20)
Racial differences in responses to interferon‐β‐1a in chronic hepatitis C unresponsive to interferon‐α: a better response in Chinese patients (2004) (20)
Entecavir plus tenofovir combination therapy for chronic hepatitis B in patients with previous nucleos(t)ide treatment failure (2016) (19)
Etiology of chronic hepatitis in France: predominant role of hepatitis C virus. (1994) (19)
Optimized threshold for serum HCV RNA to predict treatment outcomes in hepatitis C patients receiving peginterferon alfa‐2a/ribavirin (2012) (19)
GS-98-438 a double-blind, randomized, placebo-controlled study of adefovir dipivoxil (ADV) for presumed precore mutant chronic hepatitis B: 48 week results (2002) (19)
Hepatitis C virus eradication followed by HBeAg to anti-HBe seroconversion after pegylated interferon-alpha2b plus ribavirin treatment in a patient with hepatitis B and C coinfection. (2006) (19)
The predictive value of core antigen testing for the management of hepatitis C patients receiving pegylated interferon/ribavirin treatment (2004) (19)
Type II IgM monoclonal cryoglobulinemia and hepatitis C virus infection. (1991) (19)
Co-infection VIH-VHC à l'hôpital. Enquête nationale juin 2001 (2003) (19)
GS-98-437 a double-blind, randomized, placebo-controlled study of adefovir dipivoxil (ADV) for the treatment of patients with HBeAg+ chronic hepatitis B infection: 48 week results. (2001) (19)
Haemobilia causing acute pancreatitis after percutaneous liver biopsy: diagnosis by magnetic resonance cholangiopancreatography. (2001) (18)
Latent hepatitis B virus (HBV) infection in systemic necrotizing vasculitis. (1991) (18)
HBsAg quantification to predict natural history and treatment outcome in chronic hepatitis B patients. (2013) (18)
A pilot study of recombinant interferon beta-1a for the treatment of chronic hepatitis C. (2000) (18)
Two year results from a double-blind, randomized, placebo-controlled study of adefovir dipivoxil (ADV) for presumed precore mutant chronic hepatitis B (2003) (18)
Is the response to recombinant alpha interferon related to the presence of antibodies to hepatitis C virus in patients with chronic non-A, non-B hepatitis? (1990) (18)
Pegylated Interferon-α2b plus Ribavirin Therapy in Patients with Hepatitis C and Psychiatric Disorders: Results of a Cohort Study (2010) (18)
Prevalence of hepatitis C virus infection in asymptomatic anti-HIV1 negative pregnant women and their children (1993) (18)
Quantification of hepatitis B e antigen between Elecsys HBeAg and Architect HBeAg assays among patients infected with hepatitis B virus. (2013) (18)
45 HBsAg seroconversion in adefovir dipivoxil (ADV) treated chronic hepatitis B (CHB) patients (2004) (18)
Long‐term outcome of primary non‐responders to tenofovir therapy in HIV/HBV‐co‐infected patients: impact of HBV genotype G (2012) (18)
A phase 3 study comparing tenofovir alafenamide to tenofovir disoproxil fumarate in patients with HBeAg-negative, chronic hepatitis B: efficacy and safety results at week 96 (2017) (18)
Results From the Phase 2 PEARL-I Study: Interferon-Free Regimens of ABT-450/r + ABT-267 With or Without Ribavirin in Patients With HCV Genotype 4 Infection: 438 (2014) (17)
Assessment of Viral Loads in Patients with Chronic Hepatitis C with AMPLICOR HCV MONITOR Version 1.0, COBAS HCV MONITOR Version 2.0, and QUANTIPLEX HCV RNA Version 2.0 Assays (2000) (17)
Predicting efficacy and safety outcomes in patients with hepatitis C virus genotype 1 and persistently ‘normal’ alanine aminotransferase levels treated with peginterferon α‐2a (40KD) plus ribavirin (2007) (17)
903 TENOFOVIR DISOPROXIL FUMARATE (TDF) VERSUS EMTRICITABINE PLUS TDF (FTC/TDF) FOR TREATMENT OF CHRONIC HEPATITIS B (CHB) IN PATIENTS WITH PERSISTENT VIRAL REPLICATION RECEIVING ADEFOVIR DIPIVOXIL (2009) (17)
Autoimmune disorders associated with hepatitis C. (1995) (17)
Quasispecies Analysis and In Vitro Susceptibility of HBV Strains Isolated from HIV–HBV-Coinfected Patients with Delayed Response to Tenofovir (2012) (17)
[Natural history of dysthyroidism during interferon treatment of chronic hepatitis C]. (1996) (16)
Acute hepatitis induced by α-interferon, associated with viral clearance, in chronic hepatitis C (1997) (16)
Long-term results of treatment with nucleoside and nucleotide analogues (entecavir and tenofovir) for chronic hepatitis B. (2013) (16)
Dynamic Evolution of Therapy for Chronic Hepatitis C: How will Novel Agents be Incorporated into the Standard of Care? (2008) (16)
Including Ratio of Platelets to Liver Stiffness Improves Accuracy of Screening for Esophageal Varices That Require Treatment. (2020) (16)
Acute hepatitis E with severe jaundice: report of three cases. (2007) (16)
Natural history of hepatitis C and the impact of anti-viral therapy. (2000) (16)
Factors Associated With Persistent Increase in Level of Alanine Aminotransferase in Patients With Chronic Hepatitis B Receiving Oral Antiviral Therapy (2017) (16)
52 A randomized trial of telbivudine (LDT) vs. adefovir for HBeAg-positive chronic hepatitis B: Results of the primary week 24 analysis (2006) (16)
Sustained hepatitis B e antigen seroconversion in patients with chronic hepatitis B after adefovir dipivoxil treatment: analysis of precore and basal core promoter mutants. (2008) (16)
Distribution of hepatitis B virus DNA sequences in different peripheral blood mononuclear cell subsets in HBs antigen‐positive and negative patients (1994) (16)
1058 ANTIVIRAL ACTIVITY AND SAFETY OF TMC435 COMBINED WITH PEGINTERFERON ALPHA-2A AND RIBAVIRIN IN PATIENTS WITH GENOTYPE 1 HEPATITIS C INFECTION WHO FAILED PREVIOUS IFN-BASED THERAPY (2009) (16)
1415 CONFIRMATION THAT QUADRUPLE THERAPY WITH DACLATASVIR (NS5A INHIBITOR), ASUNAPREVIR (NS3 INHIBITOR) AND PEGINTERFERON/RIBAVIRIN RESULTS IN HIGH RATE OF SVR4 IN HCV GENOTYPE 1 NULL RESPONDERS (2012) (16)
425 FOUR-WEEK TREATMENT WITH GS-9256 AND TEGOBUVIR (GS-9190), ± RBV ± PEG, RESULTS IN ENHANCED VIRAL SUPPRESSION ON FOLLOW-UP PEG/RBV THERAPY, IN GENOTYPI 1A/1B HCV PATIENTS (2011) (16)
The need for histological subclassification of cirrhosis: a systematic review and meta‐analysis (2016) (15)
HBsAg Loss with Tenofovir Disoproxil Fumarate Plus Peginterferon Alfa-2A in Chronic Hepatitis B: Long-Term Results of a Global Randomized Controlled Trial (2016) (15)
Absence of effect of zidovudine on replication of hepatitis B virus in patients with chronic HIV and HBV infection. (1989) (15)
A Phase 3 Study of Tenofovir Alafenamide Compared with Tenofovir Disoproxil Fumarate in Patients with Hbeag-Negative, Chronic Hepatitis B: Week 48 Efficacy and Safety Results (2016) (15)
Treatment of chronic hepatitis B with the combination of pegylated interferon with lamivudine (2007) (15)
Genotype 1 is associated with a slower progression of fibrosis in untreqted patients with mild chronic hepatitis C (2001) (15)
Predictive value of alt levels on histological findings in chronic hepatitis C: a European collaborative study (2001) (14)
Exacerbation of multiple sclerosis after the administration of recombinant human interferon alfa. (1989) (14)
Acute pulmonary embolism: a rare complication of a large non-parasitic hepatic cyst (2004) (14)
95 Peginterferon alfa-2A (40KD) (PEGASYS®) monotherapy is more effective than lamivudine monotherapy in the treatment of HBEAG-negative chronic hepatitis B: 72-week results from a phase III, partially double-blind study of PEGASYS® alone vs PEGASYS® plus lamivudine vs lamivudine (2004) (14)
865 12 WEEK RESPONSE-GUIDED TREATMENT WITH THE NS5A INHIBITOR, GS-5885, THE NS3 PROTEASE INHIBITOR, GS-9451, PLUS PEGYLATED INTERFERON/RIBAVIRIN IN TREATMENT NAÏVE GENOTYPE 1 HEPATITIS C INFECTED PATIENTS (2013) (14)
Fatal exacerbation of chronic hepatitis B induced by recombinant alpha-interferon (1991) (14)
Role of cytokines in the assessment of the severity of chronic hepatitis C and the prediction of response to therapy. (2002) (14)
Detection of serum HBV-DNA by polymerase chain reaction (PCR) in patients before reactivation of chronic hepatitis B. (1992) (14)
503 Durability of HBeAg seroconversion following adefovir dipivoxil treatment for chronic hepatitis B (CHB) (2006) (14)
Non‐virological factors are drivers of hepatocellular carcinoma in virosuppressed hepatitis B cirrhosis: Results of ANRS CO12 CirVir cohort (2019) (14)
Baseline alt predicts histologic and serologic response in patients with HBeAg+ chronic hepatitis B treated with adefovir dipivoxil (ADV) (2002) (14)
66 HIGH SUSTAINED VIRAL RESPONSE AT 12- AND 24-WEEK FOLLOW-UP OF MK-5172 WITH PEGYLATED INTERFERON alfa-2b AND RIBAVIRIN (PR) IN HCV GENOTYPE 1 TREATMENT-NAIVE NON-CIRRHOTIC PATIENTS (2013) (14)
New therapies for hepatitis delta virus infection (2021) (14)
Accurate model predicting sustained response at week 4 of therapy with pegylated interferon with ribavirin in patients with chronic hepatitis C (2006) (14)
Hepatocellular carcinoma with normal adjacent liver. Hepatitis B virus DNA status. (1989) (14)
HBsAg kinetics of decay and baseline characteristics of HBeAg-positive patients with chronic hepatitis B following 3 years of tenofovir disoproxil fumarate (TDF) treatment (2010) (14)
Adenine arabinoside 5'-monophosphate in patients with chronic hepatitis B: comparison of the efficacy in patients with high and low viral replication. (1995) (13)
Insulin resistance: a major factor associated with significant liver fibrosis in Egyptian patients with genotype 4 chronic hepatitis C (2013) (13)
[613] VIROLOGICAL RESPONSE AT 4 AND 12 WEEKS PREDICT HIGH RATES OF SUSTAINED VIROLOGICAL RESPONSE IN GENOTYPE 1 PATIENTS TREATED WITH PEGINTERFERON a-2a (40 kD) PLUS RIBAVIRIN (2007) (13)
[Management of hepatitis B and C]. (2005) (13)
Chronic viral hepatitis (2003) (13)
Adefovir dipivoxil is effective for the treatment of cirrhotic patients with lamivudine failure (2009) (13)
Efficacy and safety of sofosbuvir-based therapies in patients with advanced liver disease in a real-life cohort (2017) (13)
Long-term (3-year) Therapy with Adefovir Dipivoxil for the Treatment of Hepatitis B e Antigen Negative Chronic Hepatitis B (2005) (13)
492 A phase II, placebo-controlled study of merimepodib (XV-497), in combination with pegylated interferon-alfa, and ribavirin in patients with chronic hepatitis C non-responsive to previous therapy with interferon-alfa and ribavirin (2004) (13)
Prevalence of Hepatitis C Virus Infection in Patients Hospitalized for Hepatitis A (1999) (13)
Lessons from a multicentre study of the detectability of viral genomes based on a two-round quality control of GB virus C (GBV-C)/hepatitis G virus (HGV) polymerase chain reaction assay. (2000) (13)
Detection of an HCV chronic carrier state without anti-HCV antibody in a blood donor during 28 monthsDécouverte d'une infection chronique par le VHC sans séroconversion chez un donneur de sang en France pendant 28 mois (2000) (12)
A Personalized Approach to Optimize Hepatitis B Treatment in Treatment-naive Patients (2010) (12)
56 ON-TREATMENT RESPONSE-GUIDED THERAPY WITH TELAPREVIR Q8H OR Q12H COMBINED WITH PEGINTERFERON ALFA-2A OR PEGINTERFERON ALFA-2B AND RIBAVIRIN IN TREATMENT-NAIVE GENOTYPE 1 HEPATITIS C (STUDY C208) (2010) (12)
O112 : HBsAg clearance after addition of 48 weeks of pegifn in HBeAg negative CHB patients on nucleos(T)ide therapy with undetectable hbvdna for at least one year: final results from ANRS-HB06 pegan study: multicenter randomized controlled phase III trial (2015) (12)
Neutralizing antibodies to interferon‐α and circulating interferon in patients with chronic hepatitis C non‐responding to pegylated interferon plus ribavirin re‐treated by pegylated interferon‐α‐2a and ribavirin (ANRS HC16 GAMMATRI substudy*) (2010) (11)
SCG10 expression on activation of hepatic stellate cells promotes cell motility through interference with microtubules. (2010) (11)
Characterization of the liver immune microenvironment in liver biopsies from patients with chronic HBV infection (2021) (11)
[Hepatitis C virus, interferon alpha, and dysthyroidism]. (1993) (11)
Quantification of genotype 4 serum samples: Impact of hepatitis C virus genetic variability (2010) (11)
O117 : Predictors of clinical response: Results from a large, randomized controlled study with tenofovir disoproxil fumarate (TDF) plus peginterferon alfa-2A (PEG) combination for chronic hepatitis B (CHB) (2015) (11)
Corrigendum to “Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3” [J Hepatol 40 (2004) 939–999] (2005) (11)
162 Role of Interferon Response During RE-Treatment of Null Responders with Boceprevir Combination Therapy: Results of Phase II Trial (2008) (11)
Interferon‐α suppresses liver cell proliferation in patients with chronic hepatitis C virus infection (2005) (10)
A randomized, controlled study of peginterferon lambda-1a/ribavirin ± daclatasvir for hepatitis C virus genotype 2 or 3 (2016) (10)
Transition of care between paediatric and adult gastroenterology. Chronic viral hepatitis. (2003) (10)
Interferon-alpha therapy for chronic hepatitis C in special patient populations. (1996) (10)
869a Simeprevir (TMC435) With Peginterferon/Ribavirin for Treatment of Chronic HCV Genotype-1 Infection in Treatment-Naive Patients: Results From QUEST-2, a Phase III Trial (2013) (10)
804 SUSTAINED VIROLOGIC RESPONSE AFTER PEGINTERFERON ALFA-2B AND RIBAVIRIN TREATMENT PREDICTS LONG-TERM CLEARANCE OF HCV AT 5-YEAR FOLLOW-UP (2008) (10)
Durability of HBeAg seroconversion following adefovir dipivoxil treatment for chronic hepatitis B (2006) (10)
Response-Guided Therapy: Optimizing Treatment now and in the Future (2008) (10)
Indeterminate third-generation recombinant immunoblot assay in hepatitis C virus infection. Group d'Etudes Moléculaires des Hépatites (GEMHEP). (1994) (10)
Large-scale viral genome analysis identifies novel clinical associations between hepatitis B virus and chronically infected patients (2019) (10)
Viral hepatitis: Impressive advances but still a long way to eradication of the disease (2014) (9)
743 The majority of patients with HBeAg-negative chronic hepatitis B treated with peginterferon alpha-2a (40KD) [PEGASYS®] sustain responses 2 years post-treatment (2006) (9)
[Discovery of a chronic HVC infection without seroconversion in a blood donor in France during 28 months]. (2000) (9)
Accumulation of Intrahepatic TNF-α-Producing NKp44+ NK Cells Correlates With Liver Fibrosis and Viral Load in Chronic HCV Infection (2016) (9)
Impact of Treatment against Hepatitis C Virus on Overall Survival of Naive Patients with Advanced Liver Disease (2014) (9)
Avoiding and managing lamivudine resistance in chronic hepatitis B: current approaches and potential strategies including pegylated interferon (2010) (9)
CD4+/CD8+ ratio of liver‐derived lymphocytes is related to viraemia and not to hepatitis C virus genotypes in chronic hepatitis C (1995) (9)
Effect of newer oral antiviral agents on future therapy of chronic hepatitis B (2010) (9)
Telaprevir in Combination With Peginterferon Alfa-2a and Ribavirin: Analyses of Pre-Defined Subpopulations in the Phase 3 Advance Trial (2011) (9)
IFI35, mir-99a and HCV Genotype to Predict Sustained Virological Response to Pegylated-Interferon Plus Ribavirin in Chronic Hepatitis C (2015) (9)
1218 HIGH SUSTAINED VIROLOGICAL RESPONSE (SVR) RATE AFTER DANOPREVIR FOR ONLY 14 DAYS ASSOCIATED WITH PEG-INTERFERON ALFA-2A AND RIBAVIRIN IN TREATMENT-NAIVE CHRONIC HCV GENOTYPE 1 PATIENTS (2011) (9)
CLINICAL—LIVER, PANCREAS, AND BILIARY TRACT Sustained Response of Hepatitis B e Antigen-Negative Patients 3 Years After Treatment with Peginterferon Alfa-2a (2009) (9)
[Pegylated interferon: new progress in treatment for chronic hepatitis C]. (2000) (9)
Reversible myopathy during successful treatment with pegylated interferon and ribavirin for acute hepatitis C (2004) (9)
[Steatosis during chronic hepatitis C: the role of insulin resistance and viral factors]. (2007) (9)
Solitary pulmonary metastasis arising thirteen years after liver transplantation for HBV-related hepatocellular carcinoma. (2006) (9)
P0795 : Safety and efficacy of sofosbuvir-containing regimens in the French observational cohort ANRS CO22 HEPATHER (2015) (9)
49 Association between HBeAg seroconversion and sustained HBV-DNA suppression in patients treated with peginterferon alpha-2a (40KD) (PEGASYS) for HBeAg-positive chronic hepatitis B (CHB) (2006) (9)
805 HCV-RNA STATUS AT WEEK 12 OF TREATMENT WITH PEGINTERFERON ALFA-2A/RBV PREDICTS SVR IN PATIENTS WITH PRIOR NON-RESPONSE TO PEGYLATED INTERFERON ALFA-2B/RBV: RESULTS FROM REPEAT STUDY (2008) (8)
Severity of liver disease among chronic hepatitis C patients: An observational study of 4594 patients in five European countries (2015) (8)
Clevudine: a promising therapy for the treatment of chronic hepatitis B (2008) (8)
Hepatitis B virus precore mutations and HBeAg negative reactivation of chronic hepatitis B after interferon therapy. (2008) (8)
Predictors associated with treatment initiation and switch in a real‐world chronic hepatitis B population from five European countries (2014) (8)
Analysis of Hepatitis B Virus Haplotype Diversity Detects Striking Sequence Conservation Across Genotypes and Chronic Disease Phase (2020) (8)
[HBsAg seroclearance: prognostic value for the response to treatment and the long-term outcome]. (2010) (8)
BILN 2061: a major step toward new therapeutic strategies in hepatitis C (2004) (8)
739 EFFECTS OF TENOFOVIR DISOPROXIL FUMARATE ON RENAL FUNCTION IN CHRONIC HBV PATIENTS IN THREE GLOBAL RANDOMIZED STUDIES (2011) (8)
Early hepatocellular carcinoma detection using magnetic resonance imaging is cost-effective in high-risk patients with cirrhosis (2021) (8)
532 SIGNIFICANT GENOTYPE-SPECIFIC ASSOCIATION OF HEPATITIS B SURFACE ANTIGEN LEVEL AND SEVERITY OF LIVER DISEASE IN PATIENTS WITH CHRONIC HEPATITIS B (2012) (8)
Chronic hepatitis B: integrating long-term treatment data and strategies to improve outcomes in clinical practice. (2011) (8)
Using Pharmacokinetic and Viral Kinetic Modeling To Estimate the Antiviral Effectiveness of Telaprevir, Boceprevir, and Pegylated Interferon during Triple Therapy in Treatment-Experienced Hepatitis C Virus-Infected Cirrhotic Patients (2014) (8)
Review article: HCV ? STAT-C era of therapy (2010) (8)
923 SAFETY AND EFFICACY OF 96 WEEKS OF TENOFOVIR DISOPROXIL FUMARATE THERAPY IN LAMIVUDINE EXPERIENCED PATIENTS (2009) (8)
[Alpha interferon-induced eczema in atopic patients infected by hepatitis C virus: 4 case reports]. (2000) (8)
Targeted long-read sequencing reveals clonally expanded HBV-associated chromosomal translocations in patients with chronic hepatitis B (2022) (8)
Virological and serological tools to optimize the management of patients with chronic hepatitis B (2016) (8)
S1001 Clearance of HCV At 5 Year Follow-Up for Peginterferon Alfa-2b ± Ribavirin Is Predicted By Sustained Virologic Response At 24 Weeks Post Treatment (2008) (8)
Comparison of the sensitivity of nested PCR in the 5' non-coding and the NS5 regions of the HCV genome. (1994) (8)
P1324 LEDIPASVIR (LDV) AND SOFOSBUVIR (SOF) COMBINATION IMPROVES PATIENT-REPORTED OUTCOMES (PRO) DURING TREATMENT OF CHRONIC HEPATITIS C (CH-C) PATIENTS: RESULTS FROM THE ION-1 CLINICAL TRIAL (2014) (8)
Recombinant human gamma-interferon in patients with chronic active hepatitis B: pharmacokinetics, tolerance and biological effects. (1990) (8)
Chronic Hepatitis B Treatment Initiation and Modification Patterns in Five European Countries: A 2-Year Longitudinal, Non-Interventional Study (2014) (7)
How to be a great reviewer: an editor's view (2008) (7)
11 Efficacy of standard-dose and fixed-dose induction peginterferon alpha-2a (40KD) (PEGASYS®) plus ribavirin (COPEGUS®) among pegylated interferon alpha-2b (12kd)/ribavirin non-responders: Interim analysis of the repeat study (2006) (7)
Fatal reactivation of hepatitis B virus mutant following cytotoxic treatment. (1994) (7)
531 TENOFOVIR DF TREATMENT IS SAFE AND WELL TOLERATED IN CHRONIC HEPATITIS B (CHB) PATIENTS WITH BASELINE DECREASED GLOMERULAR FILTRATION RATE (2012) (7)
[124] 76 WEEK FOLLOW UP OF HBeAg-POSITIVE CHRONIC HEPATITIS B PATIENTS TREATED WITH TELBIVUDINE, ADEFOVIR OR SWITCHED FROM ADEFOVIR TO TELBIVUDINE (2007) (7)
HCV eradication reduces the occurrence of major adverse cardiovascular events in hepatitis C cirrhotic patients: data from the prospective ANRS CO12 CirVir cohort (2017) (7)
Clinical trial: interferon alpha‐2b continuous long‐term therapy vs. repeated 24‐week cycles for re‐treating chronic hepatitis C (2007) (7)
Acute hepatitis induced by alpha-interferon, associated with viral clearance, in chronic hepatitis C. (1997) (7)
What is the safe duration of therapy for patients infected with HCV genotype 6? (2009) (7)
All-oral Dual Therapy with Daclatasvir and Asunaprevir in Patients with HCV Genotype 1B Infection (2014) (7)
Clevudine: a promising therapy for the treatment of chronic hepatitis B. (2008) (7)
À La Carte Interferon for Hepatitis C? (2000) (7)
Impact of age on viral kinetics of peginterferon alfa‐2a/ribavirin in chronic hepatitis C: final analysis from the PROPHESYS cohort (2014) (6)
New Recommendations of Baveno Vi Conference for the Screening of Portal Hypertension: An Independent Sequential Validation in Patients with Compensated Viral Cirrhosis Taking into Account Virological Status (Anrs Co12 Cirvir Cohort) (2016) (6)
689 LACK OF INFLUENCE OF BASELINE GENOTYPE ON ANTIVIRAL RESPONSE IN SUBJECTS WITH CHRONIC HEPATITIS B INFECTION RECEIVING TENOFOVIR DF 300 MG QD FOR 1 YEAR (2008) (6)
[Infection of ascitic fluid by perforation of a sclerodermic colon]. (1992) (6)
High rate of adefovir–lamivudine combination therapy in nucleoside-naïve patients with chronic hepatitis B in France: results of a national survey in 1730 patients (2010) (6)
21 TWO YEARS SAFETY AND EFFICACY OF TENOFOVIR DISOPROXIL FUMARATE (TDF) IN PATIENTS WITH HBV-INDUCED CIRRHOSIS (2009) (6)
Comparison of on-treatment HCV RNA during direct antiviral therapy using two different COBAS TaqMan HCV assays. (2017) (6)
Role of hepatic HCV-RNA level on the severity of chronic hepatitis C and response to antiviral therapy. (2012) (6)
[Treatment of viral hepatitis C]. (1994) (6)
502 Efficacy and safety of peginterferon alpha-2a (40KD) (PEGASYS) in patients with chronic hepatitis B who had received prior treatment with nucleos(T)IDE analogues - the pegalam cohort (2006) (6)
Steatosis in hepatitis C: What does it mean? (2003) (6)
Tenofovir Disoproxil Fumarate (TDF) Shows Similar Virologic Suppression and Safety Between Asians and Non-Asians With Chronic Hepatitis B (CHB) (2011) (6)
683 ON-TREATMENT HBSAG DECLINE IN HBEAG-NEGATIVE PATIENTS AS A PREDICTOR OF RESPONSE TO PEGINTERFERON ALFA-2A (40KD) THERAPY 3 YEARS POST-TREATMENT: POTENTIAL FOR RESPONSE-GUIDED THERAPY (2008) (6)
Impact of IL28B, APOH and ITPA Polymorphisms on Efficacy and Safety of TVR- or BOC-Based Triple Therapy in Treatment-Experienced HCV-1 Patients with Compensated Cirrhosis from the ANRS CO20-CUPIC Study (2015) (6)
1181 A phase III, partially double-blinded study evaluating the efficacy and safety of peginterferon alfa-2A (40KD) (PEGSYS®) alone or in combination with lamivudine vs lamivudine in 546 patients with HBEAG-negative/anti-HBE-positive chronic hepatitis B (2003) (6)
Combination therapy for chronic hepatitis C. (1999) (6)
S1937 Type of Response to Prior Pegylated Interferon Alfa-2b (12KD)/RBV Predicts Subsequent Response to Retreatment with Peginterferon Alfa-2a (40KD)/RBV (2008) (6)
P1061 LONG-TERM TREATMENT WITH TENOFOVIR IN TREATMENT-NAIVE OR -EXPERIENCED CHB PATIENTS IS EFFECTIVE AND WELL TOLERATED IN REAL-LIFE PRACTICE: 3 YEARS RESULTS OF THE VIREAL STUDY (2014) (6)
Tenofovir disoproxil fumarate in Asian or Pacific Islander chronic hepatitis B patients with high viral load (≥ 9 log10 copies/ml) (2015) (6)
M1923 Tenofovir Disoproxil Fumarate (TDF) Versus Emtricitabine Plus TDF for Treatment of Chronic Hepatitis B (CHB) in Subjects with Persistent Viral Replication Receiving Adefovir Dipivoxil (ADV) (2008) (6)
Virological and histological characteristics in anti-HCV positive subjects with normal transaminases levels (1995) (6)
M1913 Lack of Influence of Baseline Genotype On Antiviral Response in Subjects with Chronic Hepatitis B Infection Receiving Tenofovir Df 300 Mg Qd for 1 Year (2008) (6)
778 PHASE IIB STUDY OF BALAPIRAVIR (RG1626; NUCLEOSIDE ANALOGUE INHIBITOR OF HCV POLYMERASE) PLUS PEGINTERFERON ALFA-2A (40KD) AND RIBAVIRIN FOR CHC GENOTYPE 1: FINAL RESULTS (2010) (6)
Adefovir dipivoxil (ADV) for the treatment of patients with chronic hepatitis B (CHB) failing lamivudine (LAM) therapy (2003) (5)
241 Long-term (96 weeks) adefovir dipivoxil in HBEAG negative chronic hepatitis results in significant virological, biochemical and histological improvement (2003) (5)
TELAPREVIR-BASED REGIMENS SUBSTANTIALLY IMPROVED SVR RATES ACROSS ALL IL28B GENOTYPES IN THE ADVANCE TRIAL (2011) (5)
836 Sustained Virologic Response (SVR) in Prior Peginterferon/Ribavirin (PR) Treatment Failures After Retreatment With Boceprevir (BOC) + PR: the Provide Study Interim Results (2012) (5)
Phase 2 study of Telaprevir administered Q8 or Q12H with Peginterferon-Alfa-2A or Alfa-2B and ribavirin in treatment-naive subjects with genotype 1 hepatitis C: week 4 interim results (2008) (5)
[3 cases of polyarthritis treated with recombinant alfa interferon]. (1992) (5)
[Managing resistance to analogue antiviral drugs in the treatment of chronic hepatitis B]. (2006) (5)
Safety profile of standard- vs. high-dose peginterferon alfa-2a plus standard-dose ribavirin in HCV genotype 1/4 patients: pooled analysis from 5 randomized studies (2012) (5)
Quantitative measurement of hepatitis C virus core antigen is affected by the presence of cryoglobulins (2006) (5)
W1806 Two Years Safety and Efficacy of Tenofovir Disoproxil Fumarate (TDF) in Patients with HBV-Induced Cirrhosis (2009) (5)
O115 PEGINTERFERON LAMBDA FOR THE TREATMENT OF CHRONIC HEPATITIS B (CHB): A PHASE 2B COMPARISON WITH PEGINTERFERON ALFA IN PATIENTS WITH HBeAg-POSITIVE DISEASE (2014) (5)
[HCV non-responder patients: definition of non-response and treatment strategy]. (2007) (5)
Lack of polymerase chain reaction amplification in the 5' region of a hepatitis C virus isolate. (1992) (5)
468 Evidence for high rates of HCV and HBV related mortality in FRANCE: A large-scale national survey (2006) (5)
Effectiveness of Peginterferon Alfa-2a Therapy in HBeAg-Positive and HBeAg-Negative Patients with Chronic Hepatitis B: Final Results 3 Years Post-Treatment of the Prospective, Global, Observational S-Collate Study (2016) (5)
P0600 : Predictive factors of cirrhosis, hepatic decompensation and hepatocellular carcinoma in patients with chronic hepatitis delta (2015) (5)
Viral hepatitis: towards the eradication of HCV and a cure for HBV (2015) (5)
Treatment of chronic hepatitis C with alpha-interferon. (1992) (5)
IDDF2018-ABS-0107 Efficacy and safety of TENOFOVIR ALAFENAMIDE (TAF) at 96 weeks in chronic HBV (CHB) patients with risk factors for use of TENOFOVIR DISOPROXIL FUMARATE (TDF) (2018) (5)
[792] IMPACT OF ADEFOVIR DIPIVOXIL ON LIVER FIBROSIS AND ACTIVITY ASSESSED WITH FIBROTEST-ACTITEST IN PATIENTS WITH CHRONIC HEPATITIS B INFECTION (2007) (5)
Anti‐thyroid autoantibodies and hepatitis C virus (1994) (5)
HBeAg levels at week 24 predict response to 8 years of tenofovir in HBeAg‐positive chronic hepatitis B patients (2018) (5)
[Treatment of chronic hepatitis B]. (2004) (4)
501 CLINICAL, VIROLOGICAL, SEROLOGICAL AND HISTOLOGICAL OUTCOMES IN CIRRHOTIC PATIENTS WITH CHRONIC HEPATITIS B (CHB) TREATED WITH TENOFOVIR DISOPROXIL FUMARATE (TDF) FOR UP TO 5 YEARS (2012) (4)
866 ALS-2200, A NOVEL ONCE-DAILY NUCLEOTIDE HCV POLYMERASE INHIBITOR, DEMONSTRATED POTENT ANTIVIRAL ACTIVITY IN TREATMENT-NAÏVE PATIENTS WITH COMPENSATED CIRRHOSIS OR GENOTYPE 2–4 CHRONIC HEPATITIS C (2013) (4)
Viral hepatitis: towards the eradication of HCV and a cure for HBV (2016) (4)
Sofosbuvir‐Daclatasvir is suboptimal in patients with genotype 2 chronic hepatitis C infection: real‐life experience from the HEPATHER ANRS CO22 cohort (2020) (4)
Histological improvement in HBeAg positive chronic hepatitis B patients treated with adefovir dipivoxil (2002) (4)
909 CHARACTERISTICS OF HBeAg-POSITIVE PATIENTS WITH HBsAg LOSS/SEROCONVERSION FOLLOWING TREATMENT WITH TENOFOVIR DISOPROXIL FUMARATE (TDF) (2009) (4)
Interferon‐gamma with peginterferon alpha‐2a and ribavirin in nonresponder patients with chronic hepatitis C (ANRS HC16 GAMMATRI) (2013) (4)
Tenofovir DF (TDF) showed superior antiviral efficacy to adefovir dipivoxil in a randomized, double-blind, study for the treatment of HBeAg-negative chronic hepatitis B (CHB) (2008) (4)
538 IMPROVED PREDICTIVE VALUE FOR SUSTAINED IMMUNE CONTROL IN PEGINTERFERON ALFA-2A (40KD) (PEGASYS)-TREATED HBEAG-POSITIVE PATIENTS USING COMBINED HBSAG AND HBV DNA LEVELS AT WEEK 24 (2012) (4)
Safety and efficacy of the combination simeprevir-sofosbuvir in HCV genotype 1- and 4-mono-infected patients from the French ANRS CO22 hepather cohort (2019) (4)
Sustained Virological Response after 14 - D Ay Treatment with Danoprevir and 48-Week Treatment with Pegylated Interferon-α2A (40 Kd) plus Ribavirin (2012) (4)
Pegeinterferon alfa-2a (40 KD) (Pegasys) plus ribavirin (copegus) is an efficacious and safe treatment for chronic hepatitis C (CHC) in patients with compensated cirrhosis (2003) (4)
809 SUSTAINED VIROLOGICAL RESPONSE IS ASSOCIATED WITH ERADICATION OF HEPATITIS C VIRUS AND DECREASE IN ANTI-HCV TITER IN PATIENTS TREATED FOR CHRONIC HEPATITIS C (2008) (4)
Cheating in scientific publishing: the scourge must stop! (2008) (4)
530 HIGH EFFICACY AND SAFETY OF TENOFOVIR DF IN 441 NAIVE AND NUC-EXPERIENCED CHRONIC HEPATITIS B PATIENTS: A REAL LIFE MULTICENTER PROSPECTIVE COHORT STUDY (2012) (4)
[508] IN HEPATITIS B PATIENTS TREATED WITH EITHER ADEFOVIR OR TELBIVUDINE, MAXIMAL EARLY HBV SUPPRESSION AT 24 WEEKS PREDICTS OPTIMAL ONE-YEAR EFFICACY (2007) (4)
Patients with chronic hepatitis C without advanced fibrosis and hepatocellular carcinoma: a retrospective clinical-pathological study. (2015) (4)
774 BASELINE AND ON-TREATMENT FACTORS ASSOCIATED WITH HIGH RATES OF SUSTAINED VIROLOGICAL RESPONSE IN PATIENTS WITH AND WITHOUT CIRRHOSIS FOLLOWING TREATMENT WITH PEGINTERFERON ALFA-2A AND RIBAVIRIN (2008) (4)
48 weeks of adefovir dipivoxil (ADV) results in improvement in fibrosis and decreased progression of fibrosis in a double-blind, randomized, placebo-controlled study for the treatment of patients with HBeAg plus chronic hepatitis B. (2002) (4)
HCV infection assessed with third generation anti-HCV testing and polymerase chain reaction (1993) (4)
Hepatitis C: The role of new interferons in the era of STAT-C (2009) (4)
A dose escalating trial evaluating the safety and antiviral activity of clevudine in patients with chronic HBV infection (2003) (4)
451 TELAPREVIR IN COMBINATION WITH PEGINTERFERON ALFA-2A AND RIBAVIRIN: ANALYSES OF PRE-DEFINED SUBPOPULATIONS IN THE PHASE 3 ADVANCE TRIAL (2011) (4)
P677 HEPATIC STEATOSIS DOES NOT PREDICT REGRESSION OF LIVER CIRRHOSIS IN CHRONIC HEPATITIS B (CHB) PATIENTS TREATED WITH TENOFOVIR DISOPROXIL FUMARATE (TDF) (2014) (4)
P1127 SIMEPREVIR (TMC435) WITH PEGINTERFERON/RIBAVIRIN FOR TREATMENT OF CHRONIC HCV GENOTYPE 1 INFECTION IN TREATMENT-NAIVE EUROPEAN PATIENTS IN THE QUEST-1 AND QUEST-2 PHASE III TRIALS (2014) (4)
A Model-Based Illustrative Exploratory Approach to Optimize the Dosing of Peg-IFN/RBV in Cirrhotic Hepatitis C Patients Treated With Triple Therapy (2014) (3)
[Treatment of chronic hepatitis B]. (2011) (3)
1017 EFFICACY OF TENOFOVIR DF TREATMENT IN PATIENTS WITH A SUBOPTIMAL RESPONSE TO ADEFOVIR DIPIVOXIL (2010) (3)
631 ASSESSMENT OF SERUM HCV-RNA AT WEEK 12 POST-TREATMENT IS AS RELEVANT AS WEEK 24 TO PREDICT SVR IN HCV PATIENTS RECEIVING PEGINTERFERON PLUS RIBAVIRIN (2009) (3)
Treatment of viral hepatitis: a new era (2013) (3)
Interferon-α therapy for chronic hepatitis C in special patient populations (1996) (3)
[Natural history of hepatitis C virus infection]. (1995) (3)
Long term course and prognostic factors in HCV-related compensated cirrhosis (1998) (3)
797 EASY TO ASSESS ON-TREATMENT PARAMETERS CORRELATE WITH DEGREE OF VIROLOGICAL RESPONSE AFTER 12 WEEKS OF TREATMENT (2008) (3)
Authorship: pride and proliferation (2009) (3)
Epidemiological, clinical, biological and virological factors influencing the occurrence of hepatocellular carcinoma and validation of predictive scores in 317 HBV-related cirrhotic patients. Prospective study Cir-B nested in the ANRS CO12 CirVir cohort (2016) (3)
Targeted long read sequencing reveals the comprehensive architecture and expression patterns of integrated HBV DNA in CHB liver biopsies (2020) (3)
Adefovir dipivoxil (ADV) results in a consistent and significant improvement in liver histology and clinical status regardless of baseline knodell fibrosis score in patients with HBeAg+Chronic hepatitis B (2003) (3)
Above and beyond the Playing Field: An Interview with Hines Ward, NFL Wide Receiver (2007) (3)
1024 EFFICACY AND SAFETY OF THE COMBINATION OF ENTECAVIR (ETV)-TENOFOVIR (TDF) IN THE TREATMENT OF CHRONIC HEPATITIS B (CHB): A NATIONWIDE, RETROSPECTIVE STUDY (2010) (3)
78 VALIDATION OF CONTROLLED ATTENUATION PARAMETER (CAP) AS A NON-INVASIVE MARKER OF STEATOSIS IN 228 PATIENTS WITH CHRONIC LIVER DISEASE FROM VARIOUS CAUSES (2010) (3)
Liver cell proliferation in patients with chronic hepatitis C is reduced by interferon therapy (2000) (3)
Anamnesis and diagnosis of hepatitis C (2006) (3)
[Treatment of hepatitis C: advances and consensus]. (2002) (3)
How to write a paper: an editor's tips (2008) (3)
Recent advances in hepatology (2017) (3)
[Hepatitis B: clinical application of HBsAg quantification]. (2013) (3)
508 IS HBEAG LOSS ASSOCIATED WITH AN IMPROVED OUTCOME IN HEPATITIS B PATIENTS TREATED WITH TENOFOVIR DISOPROXIL FUMARATE (TDF) (2012) (3)
The Usefulness of Defining Rapid Virological Response by a Very Sensitive Assay (TMA) during Treatment of HCV Genotype 2/3 Infection (2015) (3)
T-25 Impact of insulin resistance on antiviral efficacy of telaprevir-based regimen in treatment-naïve genotype 1 HCV: Results from C208 sub-analysis (2011) (3)
T2003 On-Treatment Response-Guided Therapy With Telaprevir Q8h or Q12h Combined With Peginterferon Alfa-2a or Peginterferon Alfa-2B and Ribavirin in Treatment-NaïVE Genotype 1 Hepatitis C (Study C208) (2010) (3)
P0328 : Incidence, characteristics and determinants of primary liver cancer occurring during surveillance of compensated HCV cirrhosis according to sustained virological response (ANRS CO12 CirVir) (2015) (3)
Improved predictive value for sustained immune control in peginterferon alfa-2a (40KD) (PEGASYS)-treated HBeAg-positive patients using combined HBsAg and HBV DNA levels at week 24 (2012) (3)
160 Prove2 Study: Treatment of Chronic Hepatitis C with Telaprevir (TVR)in Combination with Peginterferon-Alfa-2a with or Without Ribavirin, Interim Analysis Results (2008) (3)
1192 HIGH SUSTAINED VIROLOGICAL RESPONSE RATES WITH RESPONSE-GUIDED DANOPREVIR PLUS PEGINTERFERON ALFA-2A (40KD) AND RIBAVIRIN IN TREATMENT-NAIVE, HCV GENOTYPE 1 PATIENTS: ATLAS STUDY FINAL RESULTS (2012) (3)
Factors associated with rapid progression of fibrosis following liver transplantation for hepatitis C (2003) (3)
IDDF2020-ABS-0061 Impact of treatment with tenofovir alafenamide (TAF) or tenofovir disoproxil fumarate (TDF) on hepatocellular carcinoma (HCC) incidence in patients with chronic hepatitis B (CHB) (2020) (3)
[Liver, biliary tracts and human immunodeficiency virus infection. 2: hepatobiliary complications of AIDS]. (1996) (3)
Prospective Evidence That Hepatocellular Carcinoma Surveillance in Patients with Compensated Viral Cirrhosis Increases the Probability of Curative Treatment and Survival Taking into Account Lead-Time Bias (Anrs Co12 Cirvir Cohort) (2016) (3)
Journals' impact and pecking order: tyranny and tyrannosaurs (2012) (3)
[21] INSULIN RESISTANCE IN 424 CHRONIC HEPATITIS C PATIENTS: ASSOCIATION WITH HCV REPLICATION AND ADVANCED FIBROSIS (2007) (3)
Post treatment histologic outcome in patients with chronic hepatitis C treated with recombinant alpha interferon (1993) (3)
Week 96 Efficacy and Safety Results of Tenofovir Alafenamide (TAF) Comparing to Tenofovir Disoproxil Fumarate (TDF) in Chronic Hepatitis B (CHB), HBEAG-Negative, Chronic Hepatitis B Patients: A Global Phase 3 Study (2017) (3)
[Hepatitis C and liver transplantation: fibrosis progression and treatment. Or how to improve management]. (2006) (3)
[740] ASSESSMENT OF LIVER FIBROSIS USING LIVER STIFFNESS MEASUREMENT (LSM) IN PATIENTS WITH ALCOHOLIC LIVER DISEASE (2007) (3)
CLINICAL-LIVER, PANCREAS, AND BILIARY TRACT Long-term Therapy With Adefovir Dipivoxil for HBeAg-Negative Chronic Hepatitis B for up to 5 Years (2006) (3)
Early negative tests for serum HCV RNA as a predictor of sustained response to interferon therapy in patients with chronic hepatitis C (1997) (3)
Intra-portal lymphoid nodules: A histologic lesion distinctive of chronic hepatitis C (1991) (3)
The power of one and saving private Braillon (2012) (3)
No association between IFNL3 (IL28B) genotype and response to peginterferon alfa-2a in HBeAg-positive or -negative chronic hepatitis B (2018) (3)
P0468 : Negative impact of HBV/HCV coinfection on HBV or HCV monoinfection: Data from the French cohort – ANRS CO22 hepather (2015) (3)
[Interferons. Structure, functions and therapeutic applications of interferons]. (1993) (3)
The impact of direct antiviral agent therapy on liver fibrosis in patient with advanced fibrosis related chronic hepatitis C (2018) (3)
“Total HCV core antigen assay”: a new marker of viremia and it's application in diagnosis (2002) (3)
factors Associated with the Lack of Achievement of Normal Alt in Chronic Hepatitis B (chb) Patients Treated with Tenofovir Df (tdf) for up to 5 Years : 411 (2012) (3)
Lack of mother to infant transmision of the hepatitis C virus (HCV) (1990) (2)
748 VIROLOGICAL RESPONSE AND TOLERANCE OF TENOFOVIR DF (TDF) IN THE ELDERLY IS SIMILAR TO YOUNGER PATIENTS IN REAL LIFE PRACTICE (2013) (2)
Correction to: Hepatitis B Surface Antigen Loss with Tenofovir Disoproxil Fumarate Plus Peginterferon Alfa-2a: Week 120 Analysis (2018) (2)
[Assessment of hepatitis C networks]. (2002) (2)
806 TYPE OF RESPONSE TO PRIOR PEGYLATED INTERFERON ALFA-2B (12KD)/RBV PREDICTS SUBSEQUENT RESPONSE TO RETREATMENT WITH PEGINTERFERON ALFA-2A (40KD)/RBV (2008) (2)
Hepatitis C subtype distribution in chronically infected patients with mild liver fibrosis in France: the GEMHEP study (2019) (2)
Corrigendum to “Resistance to adefovir: A new challenge in the treatment of chronic hepatitis B” [J Hepatol 43 (2005) 920–923] (2006) (2)
776 PATIENT EDUCATION IMPROVES ADHERENCE TO PEGINTERFERON AND RIBAVIRIN IN CHRONIC GENOTYPE 2 OR 3 HEPATITIS C VIRUS (HCV) INFECTION IN THE REAL-LIFE (2008) (2)
322 Tenofovir Disoproxil Fumarate (TDF) Versus Emtricitabine Plus TDF (FTC/TDF) for Treatment of Chronic Hepatitis B (CHB) in Patients with Persistent Viral Replication Receiving Adefovir Dipivoxil (2009) (2)
Gens Una Sumus (2007) (2)
Corrigendum to “Which patients with genotype 1 chronic hepatitis C can benefit from prolonged treatment with the ‘accordion’ regimen?” [J Hepatol 47 (2007) 580–587] (2008) (2)
Medical therapy of patients affected by HBeAg-negative chronic hepatitis B. (2006) (2)
[Management of chronic hepatitis C in 2008]. (2008) (2)
Safety and efficacy of tenofovir alafenamide in geriatric patients with chronic hepatitis B: experience from four ongoing phase 2 and phase 3 clinical trials (2020) (2)
Efficacy and Neurotoxicity of ARA‐AMP in CAH‐B (1990) (2)
[Pretreatment with prednisolone enhances the effect of human lymphoblastoid interferon in chronic hepatitis B]. (1998) (2)
Staging Fibrosis in Chronic Viral Hepatitis (2022) (2)
Relationship between anti-HCV antibodies measured by a quantitative riba assay and response to interferon in patients with chronic non A non B hepatitis (1991) (2)
Recombinant alpha interferon therapy for chronic hepatitis C in anti-HIV positive patients (1991) (2)
Gens Una Sumus – still (2013) (2)
436 Models to predict inflammation and fibrosis in patients with chronic hepatitis B (2004) (2)
P1084 PRESENCE OF STEATOSIS AND HBeAg-POSITIVE STATUS ARE INDEPENDENTLY ASSOCIATED WITH PERSISTENTLY ELEVATED SERUM ALT LEVELS IN CHRONIC HBV PATIENTS DURING ANTIVIRAL THERAPY (2014) (2)
Predicting Early and Sustained Virological Responses in Prior Nonresponders to Pegylated Interferon alpha-2b Plus Ribavirin Retreated With Peginterferon alpha-2a Plus Ribavirin and the Benefit-Risk Ratio of Retreatment (2013) (2)
[Type II mixed cryoglobulinemia with cutaneo-nervous vasculitis during chronic hepatitis C]. (1991) (2)
Safety and efficacy of peginterferon alpha-2b plus ribavirin in pre-cirrhotic and cirrhotic patients with chronic hepatitis C (2003) (2)
Lack of benefit of prolonging interferon therapy in patients with chronic hepatitis C without early response (1998) (2)
‘Foie cardiaque’: a new name for an old syndrome? (2008) (2)
782 HEPATIC MIRNA SIGNATURE PREDICTING SUSTAINED VIROLOGICAL RESPONSE IN CHRONIC HEPATITIS C (2011) (2)
Final analysis of the international observational S-Collate study of peginterferon alfa-2a in patients with chronic hepatitis B (2020) (2)
[Unexpected protective role of interferon-alpha against Mycobacterium tuberculosis during the course of hepatitis C antiviral therapy]. (2004) (2)
Relationship between the effector T-cell response and viremia in symptomatic chronic hepatitis C. (1998) (2)
15 TELAPREVIR (TVR) q8h OR q12h COMBINED WITH EITHER PEGINTERFERON (PEG-IFN, P) ALFA-2A OR ALFA-2B AND RIBAVIRIN (RBV, R) IN TREATMENT-NAÏVE GENOTYPE 1 HEPATITIS C: FINAL RESULTS OF THE RANDOMIZED, OPEN-LABEL, MULTICENTER PHASE 2 STUDY C208 (2010) (2)
[Hepatitis C: the recovery]. (2009) (2)
1156 48 weeks of adefovir dipivoxil (ADV) results in a consistent and significant improvement in liver histology and virological status regardless of baseline knodell fibrosis score in patients with HBEAG- chronic hepatitis B (2003) (2)
Sustained response to interferon therapy in patients with chronic hepatitis C (1993) (2)
Influence of chronic HIV infection on chronic hepatitis B-delta in intravenous drug addicts (1991) (2)
Sa1046 Efficacy of 5 Years of Tenofovir Disoproxil Fumarate (TDF) in Chronic Hepatitis B Patients With High Viral Load (HBV DNA=9 Log10 Copies/Ml) (2012) (2)
761 COMPARISON OF SERUM HBsAg DECLINES DURING TENOFOVIR DISOPROXIL FUMARATE (TDF) TREATMENT IN DIFFERENT CHRONIC HEPATITIS B (CHB) SUB-POPULATIONS (2013) (2)
Whole-genome deep sequencing of hepatitis B virus in chronic hepatitis B patients reveals single nucleotide variants associated with baseline HBV DNA levels and HBeAg status (2017) (2)
833 LIVER FIBROSIS ASSESSMENT IN CHRONIC HEPATITIS C: EVOLUTION OF CLINICAL PRACTICE IN A LARGE COHORT OF 4546 PATIENTS BETWEEN 2003 AND 2006 (2008) (2)
P.104 Durability of HBeAg seroconversion following adefovir dipivoxil treatment for chronic hepatitis B (CHB) (2006) (2)
Towards the eradication of hepatitis C virus (2012) (2)
73 WORLDWIDE EXPERIENCE TREATING CHRONIC HEPATITIS C (CHC) WITH PEGINTERFERON ALFA/RIBAVIRIN: FINAL RESULTS FROM 7163 NAIVE, MONO-INFECTED PATIENTS ENROLLED IN THE LARGE MULTINATIONAL PROPHESYS COHORT STUDY (2012) (2)
283 HCV PROTEASE INHIBITOR RESTORES INSULIN SENSITIVITY IN GENOTYPE 1 CHRONIC HEPATITIS C PATIENTS (2010) (2)
739 ALT FLARES DURING TREATMENT WITH PEGINTERFERON LAMBDA OR PEGINTERFERON alfa IN PATIENTS WITH HBeAg-POSITIVE CHRONIC HEPATITIS B INFECTION (CHB) (2013) (2)
[Factors of response to treatment with interferon-alpha in patients with chronic hepatitis C. Therapeutic perspectives]. (1995) (2)
41 S-Collate COHORT ‘REAL-LIFE’ STUDY: EFFICACY AND SAFETY OF PEGINTERFERON alfa-2a (40KD) IN 1233 PATIENTS WITH CHRONIC HEPATITIS B ACCORDING TO ASIAN AND CAUCASIAN RACE (2013) (2)
“Rebound” phenomenon after cessation of interferon therapy in chronic Non-A, Non-B (NANB) hepatitis (1990) (2)
635 INSULIN RESISTANCE AND GEOGRAPHICAL ORIGIN ARE MAJOR PREDICTORS OF LIVER FIBROSIS AND RESPONSE TO PEGYLATED INTERFERON AND RIBAVIRIN IN GENOTYPE 4 CHRONIC HEPATITIS C PATIENTS (2009) (2)
Detrimental influence of HIV on the natural history and the interferon (IFN) response rate in patients with chronic hepatitis B (CHB) (1998) (2)
[Vidarabine treatment of chronic active hepatitis associated with hepatitis B virus multiplication. A randomized multicenter study]. (1987) (2)
529 WEEK 12 HBSAG TITER DECLINE IS PREDICTIVE OF SVR IN CHRONIC HEPATITIS B PATIENTS RECEIVING PEGYLATED INTERFERON PLUS TENOFOVIR COMBINATION THERAPY (2012) (2)
A Simple Atmosphere Generating System for Experimental Storage of Fruits and Vegetables (1982) (2)
595 Evidence for eradication of HCV, assessed with transcription mediated amplification (TMA), in chronic hepatitis C patients with sustained virological response to therapy (2006) (2)
452 EFFICACY AMONG NORTH AMERICAN AND EUROPEAN HCV GENOTYPE-1 TREATMENT-NAIVE AND PREVIOUS NON-RESPONDERS AND RELAPSERS TO PEGINTERFERON/RIBAVIRIN WHEN TREATED WITH BOCEPREVIR PLUS PEGINTERFERON ALFA-2B/RIBAVIRIN (2011) (2)
Evaluation of serum HBV RNA and HBcrAg in chronic hepatitis B patients achieving different serological outcomes on tenofovir disoproxil fumarate (TDF) (2017) (2)
571 More rapid drop of HCV RNA level under therapy and better sustained response rate in Egyptian patients versus non-Egyptian patients with HCV genotype 4 (2006) (2)
IDDF2018-ABS-0105 No resistance to TENOFOVIR ALAFENAMIDE detected through 96 weeks of treatment in patients with chronic hepatitis B (2018) (2)
Things fall apart with hepatocellular carcinoma and direct-acting antivirals (2018) (2)
20 THREE YEARS OF TENOFOVIR DISOPROXIL FUMARATE (TDF) TREATMENT IN HBEAG-NEGATIVE AND POSITIVE PATIENTS WITH CHRONIC HEPATITIS B (STUDY 102 AND STUDY 103) (2010) (2)
783 DIFFERENTIAL LIVER MIRNAS EXPRESSION IN CHRONIC HEPATITIS C PATIENTS AT EARLY STAGES OF LIVER FIBROSIS (2011) (1)
The severity of histologic lesions is not related to liver HCV RNA level in patients with chronic hepatitis C (1998) (1)
Characterization of serologic responses following ALT flares in >3000 CHB patients pooled from 5 clinical trials (2020) (1)
390 TRENDS IN EPIDEMIOLOGICAL AND CLINICAL CHARACTERISTICS OF HCV-INFECTED PATIENTS OVER SIX YEARS: A FRENCH EXPERIENCE (2009) (1)
Relationship between antiviral therapy responses and hepatic venous pressure gradient changes (2002) (1)
Update on the Role of Quantitative HBsAg and HBeAg Monitoring during Peginterferon Therapy (2012) (1)
Viral Suppression is Not a risk Factor for CKD in Viral Cirrhosis (ANRS CO12 CirVir Prospective Cohort) (2016) (1)
[Interferons: structure, functions and therapeutic applications]. (1994) (1)
Steatosis in chronic hepatitis C. Authors' reply (2006) (1)
390 DIAGNOSTIC PERFORMANCE OF TRANSIENT ELASTOGRAPHY IS SIMILAR IN HEPATITIS B AND HEPATITIS C PATIENTS (2010) (1)
[487] PREDICTORS OF HBsAg REDUCTION IN HBsAg- NEGATIVE CHRONIC HEPATITIS B PATIENTS TREATED WITH PEGINTERFERON a-2a (40 kD) ALONE OR IN COMBINATION WITH LAMIVUDINE (2007) (1)
[607] A PROSPECTIVE, MULTICENTER, OBSERVATIONAL STUDY ON ADHERENCE WITH VIRAL HEPATITIS C TREATMENTS (CHEOBS): IMPACT OF PAST PSYCHIATRIC DISORDERS ON SUSTAINED VIROLOGIC RESPONSE (SVR) (2007) (1)
Characterization of HBsAg decline in the Tenofovir disoproxil fumarate (TDF) and peginterferon alfa 2A (PEG) combination study for chronic hepatitis B (CHB) (2015) (1)
[Treatment of chronic active hepatitis caused by hepatitis B virus infection]. (1988) (1)
591 A prospective, multicenter, observational study on compliance to hepatitis C treatments (CHEOBS): Characteristics of HCV-infected patients with psychiatric disorders (2006) (1)
P776 REDUCTION OF MIR-122 IN IFNL3 CT+TT CARRIERS AND DURING PROGRESSION OF FIBROSIS IN PATIENTS WITH CHRONIC HEPATITIS C (2014) (1)
Chronic HBV Infection: Interferon Therapy and Long-Term Outcomes (2018) (1)
[509] WHICH PATIENTS WITH CHRONIC HEPATITIS B ARE TREATED AND HOW: A CROSS-SECTIONAL STUDY IN FRANCE ON 1790 PATIENTS (2007) (1)
P0665 : HBV variants present in treatment naïve patients can predict response to NA therapy in immune clearance disease (2015) (1)
684 LIVER GENE EXPRESSION SIGNATURE TO PREDICT RESPONSE TO PEGYLATED INTERFERON PLUS RIBAVIRIN IN CHRONIC HEPATITIS C (2010) (1)
Genotype Specific Differences In Magnitude Of HBsAg Reduction During TDF or tenofovir alfenamide (TAF) Therapy In CHB Patients (2016) (1)
491 Peginterferon alpha-2a (40KD) (PEGASYS) reverses cirrhosis, improves fibrosis and slows progression of fibrosis in patients with HBeAg-positive or HBeAg-negative chronic hepatitis B (CHB) (2006) (1)
Quantification of HBV hepatocyte burden using novel multiplex immunofluorescence staining and image analysis reveals substantial reduction in HBV liver burden with anti-viral treatment (2022) (1)
497 FACTORS ASSOCIATED WITH REGRESSION OF CIRRHOSIS IN PATIENTS WITH CHORNIC HEPATITIS B (CHB) INFECTION TREATED WITH TENOFOVIR DISOPROXIL FUMARATE (TDF) (2012) (1)
844 IMPACT OF ANTIVIRAL THERAPY ON SURVIVAL IN PATIENTS WITH ADVANCED FIBROSIS – EXPERIENCE OF BEAUJON HOSPITAL 2000 TO 2010 (2013) (1)
418 UTILITY OF HISTORICAL DATA COMPARED TO LEAD-IN RESPONSE IN PREDICTING SUSTAINED VIROLOGIC RESPONSE IN NON-RESPONDERS AND RELAPSERS TO PEGINTERFERON/RIBAVIRIN WHEN RE-TREATED WITH BOCEPREVIR+PEGINTERFERON ALFA-2B/RIBAVIRIN (P/R) (2011) (1)
1058 INSULIN RESISTANCE: A MAJOR PREDICTOR OF SIGNIFICANT LIVER FIBROSIS IN EGYPTIAN PATIENTS WITH GENOTYPE 4 CHRONIC HEPATITIS C (2010) (1)
Impact of ribavirin dose on retreatment of chronic hepatitis C patients. (2012) (1)
Identifying residual risk of hepatocellular carcinoma following hepatitis C virus eradication in compensated cirrhosis: decision-tree and random forest models developed in the French multicenter prospective ANRS CO12 CirVir cohort (2017) (1)
781 INCIDENCE AND PREDICTORS OF HCC IN CHRONIC HEPATITIS C PATIENTS WITH CIRRHOSIS AND NON RESPONDING TO PEGINTERFERON AND RIBAVIRIN THERAPY (2009) (1)
573 Long-term outcome of hepatitis C infection after bone marrow transplantation (2003) (1)
[Treatment has a positive impact on the long-term evolution of chronic hepatitis B]. (2010) (1)
Co-infection VIH-VHC en l'an 2001 (2001) (1)
Economic analysis of early serum hepatitis C virus RNA testing in patients with chronic hepatitis C on interferon therapy. (2000) (1)
Emergency transplantation for acute reactivation of chronic hepatitis B with high viral load: role of antiviral therapy (2009) (1)
Durability of HBsAg loss with nucleotide analogs and pegylated interferon in patients infected with hepatitis B virus (2017) (1)
Characteristics of HBeAg-positive patients chronically infectedwith hepatitis b virus (HBV) who achieved hbsag loss/seroconversion following tenofovir disoproxil fumarate (TDF) treatment (2009) (1)
947 Precore and core promoter mutations or serum HBV DNA levels do not allow to distinguish true inactive HBSAG carriers from HBEAG negative chronic hepatitis B with fluctuating ALT (2003) (1)
Serum IL 10 in chronic hepatitis C (2000) (1)
Impact of hepatic steatosis and controlled attenuation parameter (CAP) on accuracy of fibrosis staging using transient elastography (2017) (1)
M1891 Quantitative HBsAg: A New Specific Marker for the Diagnosis of HBsAg Inactive Carriage (2010) (1)
[Treatment of chronic hepatitis C with interferon alpha]. (1991) (1)
05E. VIRAL HEPATITIS – E) HEPATITIS B – CLINICAL (THERAPY, NEW COMPOUNDS, RESISTANCE) S259 694 MDRD CREATININE CLEARANCE IS NOT ALTERED IN HIV-HBV CO-INFECTED PATIENTS WITH A NORMAL RENAL FUNCTION AND TREATED WITH TENOFOVIR (2008) (1)
8 Chronic viral hepatitis (2003) (1)
Impact of the Use of Drugs and Substitution Treatments on the Antiviral Treatment of Chronic Hepatitis C: Analysis of Compliance, Virological Response and Quality of Life (CHEOBS) (2009) (1)
1159 Lack of ethnic differences in response to adefovir dipivoxil therapy in HBEAG+ and HBEAG- patients with chronic hepatitis B (2003) (1)
Evaluation of trugene HBV genotyping kit (research only), a sequence based genotyping assay for determination of mutations and viral genotype (2003) (1)
[Liver, biliary tracts and human immunodeficiency virus infection. 1:q liver, HIV and hepatitis B, C and D viruses]. (1996) (1)
Intrahepatic quantification of HBV antigens in chronic hepatitis B reveals heterogeneity and treatment-mediated reductions in HBV core-positive cells (2022) (1)
447 IL28B POLYMORPHISM IS NOT ASSOCIATED WITH RESPONSE TO CONVENTIONAL INTERFERON TREATMENT AND HBSAG SEROCLEARANCE IN HBEAG-POSITIVE CHRONIC HEPATITIS B PATIENTS (2012) (1)
754 QUASISPECIES ANALYSIS OF HBV STRAINS ISOLATED FROM CHRONIC HEPATITIS B PATIENTS TREATED WITH PEG-INTERFERON+ TENOFOVIR THERAPY (2013) (1)
777 SUSTAINED VIROLOGICAL RESPONSE IS ASSOCIATED WITH A LOWER RISK OF COMPLICATIONS AND HEPATOCELLULAR CARCINOMA IN PATIENTS WITH HCV RELATED CIRRHOSIS (2008) (1)
Contribution of nucleic acid amplification techniques to the safety of blood components in France (1998) (1)
808 ASSESSMENT OF VIROLOGICAL RESPONSE AT BOTH WEEK 4 AND WEEK 12 OPTIMIZES PREDICTION OF PEGINTERFERON ALFA PLUS RIBAVIRIN.TREATMENT IN PATIENTS WITH CHRONIC HEPATITIS C (2008) (1)
Prise en charge de l'hépatite chronique B. Recommandations des pratiques cliniques EASL (European Association for the Study of the Liver) (2010) (1)
Long-Term Risk of Hepatocellular Carcinoma during Follow-Up of Patients with Chronic Hepatitis B with Normal Alanine Aminotransferase (2016) (1)
Baseline HBsAg and HBcrAg Titers Allow Peginterferon Based “Precision Medicine” in Hbeag-Negative Chronic Hepatitis B (2016) (1)
Serum tumor necrosis factor level in chronic hepatitis C (2001) (1)
Long-Term Risk of Hepatocellular Carcinoma in Patients with Chronic Hepatitis B with Normal Alanine Aminotransferase (2018) (1)
PF-03491390 INHIBITS LIVER FIBROSIS IN PATIENTS WITH CHRONIC HEPATITIS C VIRUS INFECTION VIA SUPPRESSION OF PRO-APOPTOTIC CASPASE-ACTIVA- TION. (2007) (1)
P0644 : HCC risk scores: Application of the CU-HCC, GAG-HCC and page-B scores to chronic hepatitis B (CHB) patients treated with tenofovir disoproxil fumarate (TDF) (2015) (1)
Editor's report: reflections on the first year (2008) (1)
Treatment of chronic non-A, non-B hepatitis with recombinant alpha interferon: Comparison between constant and increasing dosage (1991) (1)
Hepatitis B virus haplotype number at baseline is a predictive marker of functional cure during antiviral therapy for patients with genotypes A and D HBeAg‐positive chronic hepatitis B (2022) (1)
634 Assessment of biliary fibrosis by transient elastography in PBC and PSC patients (2006) (1)
Management of chronic hepatitis C. (2007) (1)
Peginterferon Lambda, a New Potential Therapeutic Option for the Treatment of Chronic Hepatitis B: A Phase 2B Comparison with Peginterferon Alfa in Patients with HBeAg-Positive Disease (2012) (1)
925 SAFETY AND TOLERABILITY OF 96 WEEKS OF TENOFOVIR DISOPROXIL FUMARATE (TDF) TREATMENT IN HBeAg NEGATIVE AND POSITIVE PATIENTS INFECTED WITH CHRONIC HEPATITIS B (CHB) (2009) (1)
Effect of newer oral antiviral agents on future therapy of chronic hepatitis B (2010) (1)
Comparison of effect of alfa interferon in italian patients with cryptogenetic chronic active hepatitis and in patients with posttransfusion chronic active hepatitis non A non B (1989) (1)
695 LOW RATE OF DELAYED RESPONSE IN LAMIVUDINE EXPERIENCED HIV/HBV CO-INFECTED PATIENTS TREATED WITH TENOFOVIR DISOPROXIL FUMARATE (TDF) (2008) (1)
Early virologic response (EVR) at week 8 is more predictive of sustained response (SR) to pegylated combination therapy than at week 12 (2003) (1)
Chronic Non-A, Non-B, Non-C Hepatitis in French Blood Donors Assessed with HCV Third-generation Tests and Polymerase Chain Reaction (1994) (1)
Long-term Histologic Improvement and Persistent HCV Replication in Patients with Chronic Hepatitis C Having Responded to Recombinant Alpha Interferon (1994) (1)
[What does chronic hepatitis C steatosis mean?]. (2003) (1)
Dealing with editors: ‘nice n’ easy does it every time’ (2012) (1)
Hypervariable region 1 quasispecies in chronic hepatitis C patients: influence of genotype (2001) (1)
23 The effect of peginterferon alfa-2a (40KD) on liver histology in chronic hepatitis C: A meta-analysis of individual patients data (MIPD) (2003) (0)
375 Basal core promotor (BCP) and precore mutations, HBV genotype or serum HBV DNA levels do not allow to distinguish true inactive HBSAG carriers from HBEAG negative chronic hepatitis B with fluctuating alt (2004) (0)
enofovir Is Effective Alone or With Emtricitabine in Adefovir-Treated atients With Chronic-Hepatitis B Virus Infection (0)
The Presence of BCP/PC Variants Reduces the Rate of HBsAg Loss among HBeAg-Positive CHB Patients Treated with Long-Term Tenofovir DF Therapy (2016) (0)
W1814 Safety and Tolerability of 96 Weeks of Tenofovir Disoproxil Fumarate (TDF) Treatment in HBeAg Negative and Positive Patients Infected with Chronic Hepatitis B (CHB) (2009) (0)
Hepatitis C case report (2006) (0)
Sa1495 - Hbeag Loss and Seroconversion Predictors by Baseline Clinical Features and Viral Deep Sequencing of Treatment with Tenofovir Alafenamide Fumarate (TAF) or Tenofovir Disoproxil Fumarate (TDF) after 144 Weeks (2018) (0)
P.259 Retreatment with peginterferon alpha-2a (40KD) (Pegasys®) plus ribavirin (Copegus®) in patients in whom pegylated interferon alpha-2b (12KD)/ribavirin has failed: planned week-12 efficacy and safety analysis of the repeat study (2006) (0)
533 Rantes as a immune resonse to inflammation in chronic hepatitis C (2004) (0)
Peginterferon, Ribavirin and Anti-viral Triple Therapy (2012) (0)
Serum HBV DNA level and liver histology in healthy HBSAG carriers (2001) (0)
Efficacy Among North American and European HCV Genotype-1 Treatment-NaïVE and Previous Non-Responders and Relapsers to Peginterferon/Ribavirin When Treated With Boceprevir Plus Peginterferon Alfa-2B/Ribavirin (2011) (0)
Traitement de l’hépatite chronique B Treatment of chronic hepatitis B (2008) (0)
[Clinical picture and evolution of hepatitis C]. (1996) (0)
Whole-genome sequencing of patients achieving hepatitis B virus serum antigen loss following tenofovir disoproxil fumerate (TDF) and/or pegylated-interferon α-2a (PEG) therapy (2017) (0)
1170 Kinetics of viral resistance and serum HBV DNA in patients underlamivudine therapy (2003) (0)
Reply: (2007) (0)
163 Underestimated impact of alcohol consumption on the progression of fibrosis in patients transplanted for HCV related cirrhosis: A comparative study with patients transplanted for alcohol-related cirrhosis (2006) (0)
Hepatitis B virus Resistance to Antivirals : Diagnosis and Management (2011) (0)
P.241 Treatment outcomes in patients with hepatitis C virus genotype 1a and 1b and persistently ‘normal’ alanine aminotransferase (ALT) levels receiving peginterferon alpha-2a (40KD) plus ribavirin (2006) (0)
Natural history of the hepatitis C (1999) (0)
Role of HIV and HCV infections on chronic hepatitis B in homosexual men (1991) (0)
1147 VIROLOGICAL RESPONSE AND RELAPSE RATES IN FRENCH CHC PATIENTS TREATED WITH PEGINTERFERON ALFA-2A/RIBAVIRIN: A SUB-ANALYSIS OF THE FINAL POPULATION FROM THE PROPHESYS STUDY (2012) (0)
421 FIB-4 SCORE IS A STRONGER PREDICTOR OF VIROLOGICAL RESPONSE THAN LIVER BIOPSY (METAVIR) IN HEPATITIS C GENOTYPE 1 PATIENTS: INTERIM DATA FROM THE PROPHESYS TRIAL (2011) (0)
Total HCV core antigen assay: a surrogate marker of viral replication and it's use in monitoring response to therapy (2002) (0)
Retraitement par interferon alpha recombinant des patients atteints d'hépatite chronique C (1992) (0)
Interféron et hépatite chronique non-A, non-B : état de la question (1991) (0)
Detection of hepatitis B surface antigen by a monoclonal radioimmunoassay in the serum of alcoholic patients (1988) (0)
[Hepatitis C, cirrhosis and hepatocellular carcinoma]. (2008) (0)
Pleasing and displeasing things (2010) (0)
Reply (2011) (0)
778 SUSTAINED VIROLOGICAL RESPONSE IS ASSOCIATED WITH REVERSIBILITY OF CIRRHOSIS IN CHRONIC HEPATITIS C PATIENTS (2008) (0)
PIN53 COST EFFECTIVENESS OF PEGINTERFERON ALFA-2A (40KD) AND RIBAVIRIN (RBV) FOR RE-TREATMENT OF HCV GENOTYPE I (Gl) PATIENTS WHO DID NOT RESPOND TO PREVIOUS HCV TREATMENT: A UK PERSPECTIVE (2009) (0)
O.164 Eradication of HCV and regression of fibrosis, in chronic hepatitis C patients with sustained virological response to therapy (2006) (0)
820 A FOUR GENE MOLECULAR SIGNATURE IS BETTER THAN IL28B POLYMORPHISM TO PREDICT TREATMENT RESPONSE TO PEGYLATED-INTERFERON AND RIBAVIRIN IN CHRONIC HEPATITIS C (2012) (0)
Similarities and Differences Between REPEAT and EPIC3. Authors' reply (2009) (0)
Risks of Liver Complications after a Long-Term Follow-Up in Patients with Chronic Hepatitis C with Sustained Virologic Response (2016) (0)
Treatment of chronic hepatitis B: an update (2005) (0)
Tenofovir Disoproxil Fumarate (TDF) Use in HIV/HBV Co-Infected Patients in the Setting of Decompensated Liver Disease (Dld): Retrospective Evaluation of Eight Cases (2008) (0)
Risk Factors and Characteristics of Hepatocellular Carcinoma Occuring in HCV Cirrhotic Patients after Sustained Virological Response (2016) (0)
Innovative Well Testing System for High-Rate Sour-Gas Khuff Well in the North Field, Qatar (2006) (0)
Similarities and Differences Between REPEAT and EPIC3 (2009) (0)
OP11 Final results from telaprevir phase II studies in genotype 1 treatment-naive or experienced subjects with chronic hepatitis C (2010) (0)
P1062 3-YEAR TREATMENT WITH TENOFOVIR IN REAL-LIFE IS EFFECTIVE AND WELL TOLERATED IN CHB PATIENTS, INCLUDING THE ELDERLY AND PATIENTS WITH COMORBIDITIES (2014) (0)
Treatment of Hepatitis B e Antigen-Positive Chronic Hepatitis with Telbivudine or Adefovir (2020) (0)
302 IMPACT OF A HIGH RIBAVIRIN DOSE PER WEIGHT ON RESPONSE TO RETREATMENT AFTER RELAPSE TO PEGYLATED INTERFERON PLUS RIBAVIRIN (2010) (0)
[Hepatitis C virus infection and pregnancy]. (1992) (0)
Erratum: Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial (Lancet (2014) 384 (403-13)) (2016) (0)
Machine learning identifies histologic features associated with regression of cirrhosis in treatment for chronic hepatitis B (2020) (0)
[Hepatitis C in 2007...progress and challenges]. (2007) (0)
1149 REDUCTION OF mir-122 EXPRESSION IN IL28B CT/TT CHRONIC HEPATITIS C PATIENTS WHO FAILED TO PEGYLATED-INTERFERON PLUS RIBAVIRIN TREATMENT (2013) (0)
Two year safety and tolerability of tenofovir disoproxil fumarate (TDF) treatment in HBeAg negative and HBEAG positive patients with chronic hepatitis B (CHB) (2009) (0)
Interferon-α in chronic hepatitis C [1] (multiple letters) (1998) (0)
Title page (2016) (0)
P.003 Clinical relevance of the COBAS TaqMan HBV assay (2006) (0)
The Benefits of Virosuppression on Progression of Portal Hypertension in Patients with Compensated Viral Cirrhosis (ANRS CO12 CirVir Cohort) (2016) (0)
P.245 Genotype and fibrosis stage are major predictors of sustained virological response to retreatment with pegylated combination in non-responders to standard combination therapy (2006) (0)
Adefovir dipivoxil 10 mg (ADV) results in consistent efficacy in chronic hepatitis B (CHB) patients with diverse baseline characteristics (2003) (0)
112 INCIDENCE AND PREDICTIVE FACTORS OF HEPATOCELLULAR CARCINOMA AND COMPLICATIONS IN HBV- OR HCV-RELATED COMPENSATED CIRRHOSIS. A MULTICENTER PROSPECTIVE COHORT IN 1653 PATIENTS (ANRS CO12 CirVir) (2013) (0)
Predictors of virologic relapse in patients with chronic hepatitis C (CHC) treated with peginterferon alfa-2a (40KD) (pegasys) alone or in combination with ribavirin (copegus) (2003) (0)
[New management strategies for hepatitis B]. (2002) (0)
Recombinant alpha interferon in patients with decompensated cirrhosis related to HBV (1991) (0)
P0657 : Adding tenofovir to Pegylated Interferon enhances end of treatment HBsAg loss in HBeAg negative chronic hepatitis B patients (2015) (0)
HBsAg Loss With TDF Plus PegIFN in Chronic Hepatitis B (CHB): Long-term Results of a Global Randomized Controlled Trial (2017) (0)
[Treatment of chronic viral hepatitis]. (1992) (0)
S1938 HCV-RNA Status At Week 12 of Treatment with Peginterferon Alfa-2a/RBV Predicts SVR in Patients with Prior Non-Response to Pegylated Interferon Alfa-2b/RBV: Results from Repeat Study (2008) (0)
T1990 Peginterferon Alfa-2a (40KD) Has a Wide Safety Margin in Patients Infected With Hepatitis C Virus Genotype 1: Pooled Data From Four Randomized Multicenter Studies (2010) (0)
P0523 : Modification of expression of MIR-20A, MIR-92A and MIR-122 during fibrosis in patients with chronic hepatitis C (2015) (0)
T2000 Liver Gene Expression Signature to Predict Response to Pegylated Interferon Plus Ribavirin in Chronic Hepatitis C (2010) (0)
320 COMPETITION BETWEEN DIVERGENT HEPATITIS C VIRUS STRAINS DRIVEN BY INTERNAL RIBOSOME ENTRY SITE EFFICIENCY IN LIVER AND B-CELLS (2009) (0)
P0800 : Effectiveness and safety of combination new regimens based on Sofosbuvir (SOFO) with Ribavirin (RBV), Daclatasvir (DAC) or Simeprevir (SIM) in difficult patients to treat infected with chronic hepatitis C (CHC) (2015) (0)
O.139 Two types of histologically normal liver can have different gene expression patterns: The importance of an adequate normal tissue control in gene expression studies (2006) (0)
391 ABSENCE OF INFLUENCE OF METABOLIC FACTORS ON DIAGNOSTIC PERFORMANCE OF LIVER STIFFNESS MEASUREMENT IN CHRONIC HEPATITIS B AND C (2010) (0)
S1941 Easy to Assess On-Treatment Parameters Correlate with Degree of Virological Response After 12 Weeks of Treatment (2008) (0)
Viral hepatitis in 2011: a major step forward (2011) (0)
Extrahepatic Cancer is the Second Cause of Non Liver-Related Death in Patients with Compensated Viral Cirrhosis and is Associated with Viral Replication (ANRS CO12 CirVir Prospective Cohort) (2016) (0)
O.193 Internal ribosomal entry site (IRES)-dependent tropism of hepatitis C virus (2006) (0)
Hepatocellular carcinoma (HCC) scoring system for the individualized prediction of liver cancer in 1080 HCV-related compensated cirrhosis included in the French multicenter prospective cohort ANRS CO12 CirVir (2015) (0)
834 REDUCTION OF MIR-122 EXPRESSION IS ASSOCIATED WITH IL28B RS12979860 TT POLYMORPHISM AND IS INDEPENDENT OF SUSTAINED VIROLOGICAL RESPONSE IN PATIENTS WITH CHRONIC HEPATITIS C (2012) (0)
A critical study of peirasmos in James and its implications for han in Minjung theology in light of Kierkegaard's three-stage model (2009) (0)
1215 Multivariate models predict outcome to hepatitis C virus therapy at baseline and at weeks 4 and 8 (2003) (0)
Reply (1993) (0)
392 LIVER STIFFNESS IS ASSOCIATED WITH CLINICAL OUTCOME OF HCV RELATED CIRRHOSIS (2009) (0)
Demonstration of hepatitis B virus DNA using polymerase chain reaction in serum and liver after loss of HBs Ag induced by antiviral therapy (1989) (0)
827 EFFICACY OF PEGINTERFERON ALPHA-2a AND RIBAVIRIN IN HIV/HCV CO-INFECTED PATIENTS: SUBANALYSIS OF HEPATYS, FRENCH NATIONAL SURVEY (2008) (0)
2010: reflections, changes and ghosts (2010) (0)
Therapeutic options for chronic hepatitis B in 2013 (2013) (0)
[Genetic variability of the hepatitis C virus: clinical implications]. (2000) (0)
[Interferon and chronic non-A, non-B hepatitis: status of the problem]. (1991) (0)
[Treatment of hepatitis B]. (2002) (0)
Precore and Basal Core Promoter Mutants Improve the Diagnostic Performance of Fibroscan® or Fibrotest® to Predict Significant Fibrosis in Chronic Hepatitis B Patients (2016) (0)
634 IMPACT OF THE DRUG USE AND SUBSTITUTION TREATMENTS ON THE ANTIVIRAL TREATMENT OF CHRONIC HEPATITIS C: ANALYSIS OF ADHERENCE, VIROLOGICAL RESPONSE AND QUALITY OF LIFE (2009) (0)
Efficacy, Safety and UK Cost-Effectiveness in Treatment-Naive Patients with F2 Fibrosis Treated with Telaprevir (TVR; T) in Combination with Peginterferon (P) and Ribavirin (R) vs Peginterferon and Ribavirin Alone: 428 (2012) (0)
P0626 : The analysis of the expression of A2M, COL1A1, MMP2 and CHI3L identifies significant fibrosis in patients with chronic hepatitis B (2015) (0)
Interferon for HBeAg-negative chronic hepatitis B: Teaching an old trick to an old dog? (2005) (0)
Treatment of chronic viral hepatitis. (1992) (0)
Installation measures for rupture tests blade of a turbomachine (2012) (0)
Chapter 20. Treatment of Chronic Hepatitis B (2007) (0)
Predictors of HBeAg loss and seroconversion by baseline clinical features and viral deep sequencing after 144 weeks of treatment with Tenofovir Alafenamide or Tenofovir Disoproxil Fumarate (2018) (0)
[Clinical aspects of infection by non-A, non-B hepatitis (C) virus]. (1990) (0)
Hypervariable region 1 (HVR 1) quasispecies outcome in patients with chronic hepatitis C (2001) (0)
412 THE USEFULNESS OF DEFINING RVR BY A VERY SENSITIVE ASSAY DURING THE TREATMENT OF HCV GENOTYPE 3 INFECTION; A COMPARISON OF TMA AND AMPLICOR (2011) (0)
[Treatment of patients with chronic hepatitis C who have not been previously treated]. (2002) (0)
802 IMPACT OF PSYCHIATRIC DISORDERS ON ADHERENCE TO TREATMENT, QUALITY OF LIFE AND VIROLOGICAL RESPONSE IN PATIENTS WITH CHRONIC HEPATITIS C VIRUS INFECTION (2008) (0)
Relevance of total HCV core antigen testing for monitoring and predicting patients response (2002) (0)
Measuring serum HCV RNA in clinical samples : a specificity and sensitivity study (1998) (0)
Effect of zidovudine on hepatitis B virus (HBV) replication in patients with chronic HIV and HBV infection (1989) (0)
FRI-149-Comprehensive transcriptome analysis of liver biopsies from chronically infected HBV patients (2019) (0)
P0768 : Late mortality in treatment-experienced cirrhotic patients treated with triple therapy including boceprevir or telaprevir in a real-life cohort - ANRS Co 20 cupic (2015) (0)
Usefulness of the SAF score to characterize NAFLD/NASH in non-cirrhotic HCV patients (2022) (0)
RECENT ADVANCES IN CLINICAL PRACTICE STEATOSIS IN CHRONIC HEPATITIS C: WHY DOES IT REALLY MATTER? (2005) (0)
Liver steatosis is not associated with fibrosis in patients with chronic HCV infection (2003) (0)
Hepatitis B and D (2006) (0)
410 Gene expression profiling of liver fibrosis in patients with hepatitis C virus chronic infection using a large scale real-time RT-PCR approach (2003) (0)
388 Gene expression profiling of liver fibrosis in patients with chronic HCV infection using a large scale real-time RT-PCR approach (2004) (0)
635 Efficacy and Safety of the Combination of Entecavir (ETV)-Tenofovir (TDF) in the Treatment of Chronic Hepatitis B (CHB): A Nationwide, Retrospective Study (2010) (0)
420 INFLUENCE OF GENDER ON VIRAL LOAD ACCORDING TO AGE IN PATIENTS WITH CHRONIC HEPATITIS C: A POSSIBLE EFFECT OF HORMONAL FACTORS (2009) (0)
Hepatitis C virus and transplantation. (2000) (0)
P.009 Epidemiological characteristics of HBV inactive chronic carriers and comparison with hbe antigen negative chronic hepatitis B patients (2006) (0)
P0579 : Epidemiological, clinical and virological features of hepatitis delta virus infection in France (2015) (0)
O.048 Treatment of chronic hepatitis B with the combination of pegylated interferon with a nucleoside/nucleotide analogue (2006) (0)
THU-205-Evaluation of HBV outcomes after treatment discontinuation from 4 phase 3 studies (2019) (0)
P0656 : Add on peginterferon to adefovir enhances HBsAg loss in inactive HBV carriers (2015) (0)
Randomised controlled trial of alfa interferon in chronic active hepatitis non A non B (1989) (0)
682 HBVDNA SUPPRESSION INDUCED BY PEGINTERFERON ALFA-2A (40KD) BUT NOT BY LAMIVUDINE RESULTS IN HBSAG LOSS AND SEROCONVERSION AT 3 YEARS POST-TREATMENT (2008) (0)
PEGINTERFERON ALFA-2A (40KD) (PEGIFN alpha 2A) HAS A WIDE SAFETY MARGIN IN COMBINATION WITH RIBAVIRIN (RBV) 1000/1200 MG/DAY IN PATIENTS INFECTED WITH HCV GENOTYPE 1: POOLED ANALYSIS OF DATA FROM FOUR RANDOMIZED MULTICENTER STUDIES (2009) (0)
P661 APRI AND FIB-4 VS HISTOLOGY IN CHB PATIENTS IN TENOFOVIR DISOPROXIL FUMARATE (TDF) CLINICAL TRIALS (2014) (0)
[Treatment "à la carte" of chronic hepatitis B]. (2008) (0)
A phase I/II dose escalating trial evaluating safety, tolerability, pharmacokinetics and antiviral activity of clevudine in patients chronically infected with HBV (2003) (0)
Treating HBeAg-positive chronic hepatitis B (2003) (0)
316 IN VIVO ENDOPLASMIC RETICULUM STRESS IN PATIENTS WITH CHRONIC HEPATITIS C (2009) (0)
[514] PREDICTION OF LIVER HISTOPATHOLOGY BY NON-INVASIVE MODELS IN HBeAg-POSITIVE AND HBeAg-NEGATIVE CHRONIC HEPATITIS B (2007) (0)
[Management of chronic hepatitis in 2008]. (2008) (0)
Impact of IL28B, APOH and ITPA Polymorphisms on Ecacy and Safety of TVR- or BOC-Based Triple Therapy in Treatment-Experienced HCV-1 Patients with Compensated Cirrhosis from the ANRS (2016) (0)
[Benign recurrent cholestasis]. (1985) (0)
[Treatment of chronic hepatitis B]. (2004) (0)
On-treatment decline in HBeAg level at week 24 predicts for HBeAg seroconversion during long-term tenofovir therapy for HBeAg-positive CHB (2017) (0)
Safety of peginterferon alpha-2a (40KD) (PEGASYS (R)) [PEG-IFN alpha-2a (40KD)] plus ribavirin (COPEGUS (R)) among pegylated interferon alpha-2b (12KD)/ribavirin non-responders: Interim analysis of the repeat study (2006) (0)
835 GLOBAL ANALYSIS OF LIVER MIRNAS EXPRESSION IN CHRONIC HEPATITIS C LEADING TO A SIGNATURE TO PREDICT RESPONSE TO TREATMENT (2012) (0)
83 ALTERED EXPRESSION OF MICRORNAS (MIRNAS) IN LIVERS FROM PATIENTS WITH CHRONIC HEPATITIS C (2009) (0)
Large-scale viral genome analysis identifies novel clinical associations between hepatitis B virus and chronically infected patients (2019) (0)
Treatment of chronic hepatitis c. (2004) (0)
Aspects cliniques de l'infection par le virus non-A non-B (C) (1990) (0)
Utility of Historical Data Compared to Lead-in Response in Predicting Sustained Virologic Response in Non-Responders and Relapsers to Peginterferon/Ribavirin When Re-Treated With Boceprevir+Peginterferon Alfa-2B/Ribavirin (PR) (2011) (0)
846 CHARACTERIZATION OF THE EARLY VIRAL KINETICS IN COMPENSATED CIRRHOTIC TREATMENT-EXPERIENCED PATIENTS TREATED WITH BOCEPREVIR AND TELAPREVIR (2013) (0)
597 Genotype and fibrosis stage are major predictors of sustained virological response to retreatment with pegylated combination in non responders to standard combination therapy (2006) (0)
P697 SERUM LEVELS OF HEPATITIS B SURFACE ANTIGEN (HBsAg) PREDICT HEPATIC FIBROSIS SEVERITY IN E ANTIGEN-POSITIVE CHRONIC HEPATITIS B (HBeAg+VE CHB) PATIENTS (2014) (0)
Use of noninvasive biomarkers to assess fibrosis regression in cirrhotic patients during nucleos(t)ide therapy (2018) (0)
Characterization of HBsAg decline by genotype in patients with chronic hepatitis B (CHB) treated with tenofovir disoproxil fumurate (TDF) for up to 4 years (2011) (0)
T1958 Liver Gene Expression Signature of Mild Fibrosis in Chronic Hepatitis C (2010) (0)
738 HIGHEST RATES OF RESPONSE AT WEEK 72 OF THE NEPTUNE STUDY ARE ACHIEVED WITH PEGINTERFERON ALFA-2A 180 μG FOR 48 WEEKS (2011) (0)
575 Retreatment with peginterferon α-2a (40KD) (PEGASYS®) plus ribavirin (COPEGUS®) in pegylated interferon α-2b (12KD)/ribavirin non-responders with cirrhosis/advanced fibrosis: Repeat interim analysis (2006) (0)
P0794 : Relationship between HCV genotype, liver co-morbidities and fibrosis in the French cohort ANRS CO22 HEPATHER (2015) (0)
Early antiviral response to alpha interferon therapy in patients with chronic hepatitis C. Relationship with genotype and dose of interferon (1998) (0)
128 DIAGNOSTIC PERFORMANCE OF TRANSIENT ELASTOGRAPHY (FIBROSCAN) TO IDENTIFY PATIENTS ELIGIBLE FOR ANTIVIRAL TREATMENT IN CHRONIC HEPATITIS B (2011) (0)
Short communication Influence of genotype on hepatitis B surface antigen kinetics in hepatitis B e antigen-negative patients (2009) (0)
Efficacy of a second course of alpha interferon in patients with chronic hepatitis C (1994) (0)
632 MONITORING VIROLOGIC ON TREATMENT RESPONSE TO PREDICT TREATMENT OUTCOME IN PATIENTS WITH CHRONIC HEPATITIS C: REALTIME PCR ASSAYS AND BDNA/TMA PROVIDE THE SAME PERFORMANCES (2009) (0)
1083 FACTORS ASSOCIATED WITH FIBROSIS IN CHRONIC HEPATITIS C FEMALE PATIENTS: IMPACT OF MENOPAUSE (2010) (0)
Chapter 23. Hepatitis C (2007) (0)
Ultrasonic scaler: possible route for hepatitis C virus transmission (2002) (0)
Hepatitis C: current status, future progress (1998) (0)
Reply: (2009) (0)
P0860 : The impact of interferon-free regimens on employment rate during treatment in patients with chronic hepatitis C (2015) (0)
Interferon- in Chronic Hepatitis C (1998) (0)
Apoptosis and tumor necrosis factor alpha levels in chronic hepatitis C parallel the histological activity index (2003) (0)
A gentle life (2009) (0)
P.112 Response is sustained two years post-treatment in the majority of patients with HBeAg-negative chronic hepatitis B treated with peginterferon alpha-2a (40KD) [PEGASYS®] (2006) (0)
Use of ARA-AMP in liver transplant patients with HBV graft infection (1991) (0)
P0605 : Genotype specific variation in the basal core promoter and pre core regions impacts HBeAg levels during immune clearance disease (2015) (0)
Safety and efficacy in lamivudine experienced chronic hepatitis B (CHB) patients treated for two years with tenofovir disoproxil fumarate (2009) (0)
620 IDENTIFYING PATIENTS WITH A HIGH LIKELIHOOD OF ACHIEVING AN SVR FOLLOWING RE-TREATMENT WITH PEGINTERFERON ALFA-2A (40KD) PLUS RIBAVIRIN: USE OF POSITIVE PROGNOSTIC FACTORS (PPF'S) (2009) (0)
Treatment of chronic hepatitis B (2005) (0)
640 IN VIVO LIVER ENDOPLASMIC RETICULUM STRESS IN CHRONIC HEPATITIS C (2010) (0)
321 Safety and Efficacy of 96 Weeks of Tenofovir Disoproxil Fumarate Therapy in Lamivudine Experienced Patients (2009) (0)
The assessment of liver fibrosis stage by two-dimensional shear wave ultrasound and Transient Elastography in patients with chronic liver disease (2017) (0)
Efficacy of tenofovir disoproxil fumarate treatment in patients with a suboptimal response to adefovir dipivoxil (2010) (0)
Asian patients with HBeAg-negative chronic hepatitisB respond well to peginterferon alfa-2a (40 KD)(PEGASYS®) treatment (2006) (0)
Hepatitis B precore virus mutations and HBeAg negative reactivation after interferon therapy in chronic hepatitis B (1993) (0)
Reply: (2008) (0)
Current Management of Patients with HCV Genotype 1 (2021) (0)
P.232 Egyptian patients have better sustained response and more rapid drop of HCV RNA level than non-Egyptian patients with HCV genotype 4 (2006) (0)
Serum TNFA and TGF b levels in patients with chronic hepatitis C reflect the severity of the disease (2000) (0)
Cytokine-chemokine signiture and severity of chronic hepatitis C (2003) (0)
M1898 In Vitro Susceptibility of HBV Strains Isolated From HBV Patients With Primary Nonresponse to Adefovir (2010) (0)
Observational study of patients treated for chronic hepatitis C in France (2003) (0)
Is Interferon a Valuable First‐Line Therapy for HBeAg‐Positive HBV? (2010) (0)
CLINICAL-LIVER, PANCREAS, AND BILIARY TRACT Eradication of Hepatitis C Virus in Patients Successfully Treated for Chronic Hepatitis C (2008) (0)
Responses to peginterferon alfa-2a (40KD) (PEGASYS) treatment are durable in Asian Patients with HBeAg-Negative CHB: 12 month Follow-Up Data from a large Randomised Study (2006) (0)
P0610 : Dynamic prediction of inactive chronic hepatitis B using repeated HBsAg and HBV DNA level measurements through long-term follow-up (2015) (0)
820Triple Combination Treatment With Peginterferon Lambda-1a, Daclatasvir and Ribavirin for 12 Weeks in Patients Infected With HCV Genotype 1b (2014) (0)
1103 A 4 SERUM PROTEIN SIGNATURE FOR THE DIAGNOSIS OF MILD FIBROSIS IN CHRONIC HEPATITIS C (HEPACHRONIX STUDY) (2013) (0)
1171 Molecular epidemiology of hepatitis B virus in patients with HBEAG-negative/anti-HBE-positive chronic hepatitis B from different geographical areas. Data from the PEGASYs® study in HBE-antigen-negative CHB (2003) (0)
Predictors of progression of liver disease in chronic hepatitis C patients with minimal fibrosis: kinetic of serum tumor necrosis factor and transforming growth factor serum levels (2002) (0)
Analysis of HBV full-genome haplotypes from immune tolerant-, immune clearance-, and immune resolution phase of chronic hepatitis B virus disease (2020) (0)
INFLUENCE DE L'INFECTION HIV SUR L'HEPATITE NON-A NON-B CHEZ LES TOXICOMANES (1993) (0)
Reply: (2007) (0)
M1782 Characteristics of HBeAg-Positive Patients with HBsAg Loss/Seroconversion Following Treatment with Tenofovir Disoproxil Fumarate (TDF) (2009) (0)
492 HBeAg and HBV DNA kinetics in HBeAg clearance with peginterferon alpha-2a (40KD) (PEGASYS) treatment for HBeAg-positive chronic hepatitis B (CHB) (2006) (0)
377 Evaluation of the realquant® HBV-DNA assay (realtime PCR) (2004) (0)
[526] ROLE OF HIV COINFECTION IN MORTALITY RELATED TO HEPATITIS C AND HEPATITIS B IN FRANCE (2007) (0)
323 Two types of histologically normal liver can have marked difference in gene expression profiles: Importance of an adequate normal tissue control in gene expression studies (2006) (0)
Health-Related Quality of Life (HRQL) and Health Utilities (HU) of Patients with Chronic Hepatitis C (CH-C) Treated with an Interferon (IFN)-Free Regimen Containing Ledipasvir (LDV) and Sofosbuvir (SOF): 568 (2014) (0)
The effect of peginterferon alfa-2a (40 KD) on liver histology in chronic hepatitis C: A meta-analysis of individual patients data (2003) (0)
HBV : Clinical Characteristics of Patients who Developed HCC While Receiving Tenofovir Disoproxil Fumarate (TDF) Up to 288 Weeks of Therapy (2013) (0)
[How should hepatitis C be treated? Treatment of hepatitis C with interferon]. (1997) (0)
[Treatment of chronic hepatitis B]. (2006) (0)
387 HEPATITIS DELTA IN FRANCE: RESULTS IN 188 PATIENTS ON THE FRENCH HEPATITIS DELTA NETWORK (2011) (0)
542 THE ENTEBE STUDY: SAFETY AND EFFICACY OF ENTECAVIR PLUS TENOFOVIR IN ADULTS WITH CHRONIC HEPATITIS B AND PREVIOUS NUCLEOS(T)IDE TREATMENT FAILURE (2012) (0)
INTERFERON-ALPHA IN CHRONIC HEPATITIS C. AUTHOR'S REPLY (1998) (0)
[Chronic hepatitis B: which patients should be treated and how?]. (2005) (0)
Chronic hepatitis B (2012) (0)
ABO blood group does not influence Child‐Pugh A cirrhosis outcome: An observational study from CIRRAL and ANRS CO12 CIRVIR cohorts (2022) (0)
PIN6 AN OBSERVATIONAL HEALTH ECONOMIC ANALYSIS OF THE COMBINED THERAPY WITH PEGINTERFERON ALPHA-2A (PEGASYS®) AND RIBAVIRIN IN PATIENTS WITH CHRONIC C HEPATITIS (CHC) IN A REAL LIFE SETTING (2008) (0)
376 Evaluation of the increased sensitivity of the versant® HBV DNA 3.0 assay with serum samples routinely tested with cobas amplicor HBV monitor (2004) (0)
Long-term follow-up of patients with chronic hepatitis(who showed nonresponse relapse or partial response after alpha interferon therapy (1999) (0)
[Post-hepatitis B, B-D and C cirrhosis]. (1991) (0)
Evaluation of the virological response during PEG-IFN/RIB treatment by HCV NAT or total HCV core AG testing leads to similar clinical decisions (2003) (0)
Hepatitis B and Hepatitis C in 2004 (2004) (0)
First European Young Hepatologist Workshop: topics and advances. (2011) (0)
P.065 Precore and core promoter mutations or serum HBV DNA levels do not allow to distinguish true inactive HBsAg carriers from HBeAg negative chronic hepatitis B with fluctuating ALT (2006) (0)
A Microrna-Based Diagnostic Tool to Predict Advanced Fibrosis and Cirrhosis in Patients with Chronic Hepatitis B and C (2016) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Patrick Marcellin?

Patrick Marcellin is affiliated with the following schools:

Université Paris Cité
Learning Planet Institute
Paris Diderot University